USRE35321E - Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity - Google Patents
Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity Download PDFInfo
- Publication number
- USRE35321E USRE35321E US07/951,720 US95172092A USRE35321E US RE35321 E USRE35321 E US RE35321E US 95172092 A US95172092 A US 95172092A US RE35321 E USRE35321 E US RE35321E
- Authority
- US
- United States
- Prior art keywords
- group
- alkyl
- aryl
- salt
- tetrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a compound having an aldose reductase inhibitory activity and more specifically to a tetrazoleacetic acid derivative and an aldose reductase inhibitor which comprises the tetrazoleacetic acid derivative as an effective component and which is effective as a preventive medicine and/or remedy for diabetic complications as well as a method for alleviating or reducing diabetic complications.
- aldose reductase inhibitors are effective for prevention and/or treatment of diabetic copmplications. This is detailed in the article of Dr. Tsuyoshi TANIMOTO [Division of Biological Chemistry and Reference Standards, National Institute of Hygienic Sciences] (see Farumashia, 1988,24 No. 5, pp. 459-463). This article discloses the chemical structures and 50% inhibitory concentrations (IC 50 ) of representative aldose reductase inhibitors such as Alrestatin, Tolrestat, 4-Isopropyl-BFOC, Sorbinil, M-79175, Alconil, ADN-138, Epalrestat, CT-112 and Statil.
- IC 50 inhibitory concentrations
- R 1 represents a hydrogen atom or a group: --A--COOR 5 (wherein A represents an alkylene group having 1-4 carbon atoms and R 5 represents a hydrogen atom or a lower alkyl group) and R 2 , R 3 and R 4 may be the same or different and each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a phenyl group, a phenoxy group, a nitro group, a residue represented by the formula: NHCO-COOR 6 (wherein R 6 represents a hydrogen atom or a lower alkyl group) or a residue represented by the following formula: ##STR3## have very high aldose reductase inhibitory activity and already filed a patent application (Japanese Patent Application Serial No. Hei 1-70520).
- an object of the present invention is generally to provide a compound which shows excellent aldose reductase inhibitory activity, has low toxicity to organisms and is quite effective as a preventive medicine and/or remedy for diabetic complications and more specifically to provide a tetrazoleacetic acid derivative.
- Another object of the present invention is to provide an aldose reductase inhibitor which comprises the tetrazoleacetic and derivative as an effective component ane which is effective as a preventive medicine and/or remedy for diabetic complications.
- a further object of the present invention is to provide a method for alleviating or reducing symptoms related to diabetic complications.
- R 1 represents a hydrogen atom or an alkyl group
- R 2 represents a hydrogen atom, an alkyl group, an aralky group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--] except for [5-(2-thieny
- aldose reductase inhibitor which comrpises a tetrazoleacetic acid derivative represented by the following general formul (II): ##STR5##
- R 1 represents a hydrogen atom or an alkyl group
- R 2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --
- R 1 represents a hydrogen atom or an alkyl group
- R 2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O
- the alkyl group represented by R 1 or R 2 is, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl group;
- the aralkyl group includes, for instance, phenylpropyl and benzyl group;
- examples of the alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and t-butoxy groups;
- examples of the alkoxyalkyl groups are methoxymethyl and butoxymethyl groups;
- the haloalkyl groups are, for instance, mono-, di or tri-haloalkyl groups such as chloromethyl, bromomethyl, fluoromethyl and chlorobutyl groups;
- the alkyl or aryl thio groups are, for instance, methylthio, ethylthio, butylthio and phenylthio groups;
- salts of the foregoing compounds represented by Formulae (I) and (II) wherein R 1 is a hydrogen atom are pharmaceutically acceptable ones and typical examples thereof include inorganic salts such as alkali metal salts (for instance, sodium salts and potassium salts), alkaline earth metal salts (for instance, calcium salts and magnesium salts) and ammonium salts; and organic salts such as organic amine salts (for instance, triethylamine salts, pyridine salts and ethanolamine salts) and salts with basic amino acids, for instance, arginine.
- inorganic salts such as alkali metal salts (for instance, sodium salts and potassium salts), alkaline earth metal salts (for instance, calcium salts and magnesium salts) and ammonium salts
- organic salts such as organic amine salts (for instance, triethylamine salts, pyridine salts and ethanolamine salts) and salts with basic amino acids, for instance, arginine.
- the aldose reductase inhibitors according to the present invention comprises, as an essential component, at least one compound represented by the foregoing general formula (II) and are effective as preventive medicines and/or remedies for diabetic complications.
- diabetes complications means a variety of pathema such as peripheral disorder, retinopathy, nephrosis, cataract and keratopathy.
- pathema such as peripheral disorder, retinopathy, nephrosis, cataract and keratopathy.
- the aldose reductase inhibitors of the present invention can suppress the sorbitol-pproduction through strong inhibition of the activity of the aldose reductase which catalyzes the sorbitor-production in the foregoing polyol metabolic pathway and thus show excellent preventive and/or treating effects for these various diabetic complications.
- the dose of the compounds of formulae (I) and (II) is appropriately determined depending on the conditions or symptoms of patients to be treated, but in general ranges from 1 to 1,000 mg per day for adult which is administered at one time or over several times.
- the compounds may be administered through any route for medication such as oral administration, subcutaneous injection, intravenous injection and local administration.
- the aldose reductase inhibitors of the present invention may usually comprise in addition to the foregoing compounds as the essential components, pharmaceutically acceptable carriers, vehicles and other additives.
- the inhibitors of the invention may be used in any dosage form such as tablets, powder, fine particles, granules, capsules, pills, liquid preparations, solutions and suspension for injection and eye drops.
- the reaction scheme I shows the tetrazole ring formation reaction in which N-aryloylaminoalkyl carboxylate is racted with a chlorinating agent such as phosphorus pentoxide, thionyl chloride or thionyl chloride/N,N dimethylformamide to obtain a corresponding imidoyl chloride compound and then the product is reacted with sodium azide to obtain an intended compound of Formula (I).
- the reaction for obtaining the imidoyl chloride can be carried out in an organic solvent such as benzene, toluene or methylene chloride. In general, the reaction is preferably performed at a temperature of not more than room temperature.
- soidum azide in an amount of 2 to 6 times that of the imidoyl chloride as an intermediate.
- the cyclization reaction is in general performed at room temperature in N,N-dimethylformamide.
- the reaction scheme 2 means that the compounds of formula (I) in which R 1 is a hydrogen atom may be prepared by hydrolysis of the carboxylic acid ester obtained in the reaction scheme 1.
- the hydrolysis can be performed in the presence of a base such as sodium hydroxide or potassium hydroxide or an acid such as hydrochloric acid. sulfuric acid, acetic acid or trifluoroacetic acid.
- the compounds of Formula (I) Prepared according to the foregoing method are separated and purified by a chemical operation commonly employed such as extraction, recrystallization and/or column chromatography and the products thus separated and purified are used as essential components for the aldose reductase inhibitors of the present invention.
- Example (1-1) 0.5 g (2.2 mM) of methyl [5-(2-thienyl)tetrazol-1-yl) acetate obtained in Example (1-1) was dissolved in 3 ml of methanol, 1 ml of a 4 N aqueous sodium hydroxide solution was added to the resulting solution at room temperature and the mixture was refluxed with heating for one hour. After cooling the mixture to room temperature, it was diluted with water, then impurities were removed with ethyl acetate and the aqueous phase was separated.
- the resulting solution was dropwise added to a suspension of 410 mg (6.3 mM) of sodium azide in 3 ml of anhydrous N,N dimethylformide at a temperature of the suspension ranging from 5° to 10° C. over 30 minutes with stirring. After the dropwise addition, the reaction mixture was stirred for additional 30 minutes at room temperature, poured into ice-water and extracted with ethyl acetate. The organic phase obtained was washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure.
- the resulting solution was dropwise added to a suspension of 800 mg (12.3 mM) of sodium azide in 5 ml of anhydrous N,N-dimethylformamide as a temperature of the suspension ranging from 5° to 10° C. over 30 minutes and stirring. After the dropwise addition, the reaction mixture was stirred for additional 30 minutes at room temperature, poured into ice-water and extracted with ethyl acetate. The organic phase obtained was washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure.
- the aldose reductast inhibitor of the present invention shows excellent aldose reductase inhibitory effect and has low toxicity. Therefore, it can be used as a medicine for preventing and/or treating mammalian inclusive of man suffering from diabetic complications such as neural disorders, nephrosis, cataract and retinopathy with safety.
- aldose reductase was determined according to a partially modified method of J.H. Kinoshita et al (J. Bio. Chem., 1965, 240, p. 877). More specifically, 0.1 ml of DL glyceraldehyde (final concentration: 10 mM) was added to 0.9 ml of 100 mM sodium potassium phosphate buffer (pH 6.2) which contained lithium sulfate (final concentration: 400 mM), reduced nicotinamide adenine dinucleotide phosphate (final concentration: 0.15 mM), the enzyme solution, and the compound to be evaluated (final concentration: 10 -6 M, 10 -7 M or 10 31 8 M), and then the reaction was conducted at 30° C.
- the results are expressed in the percentage obtained while the value obtained on the control to which any drug was not administered is defined to be 100.
- Each compound to be tested was suspended to 0.5% sodium carboxymethyl cellulose solution and the resulting suspension was orally administered to 6-weeks-old male MCH mice (5 animals per test group).
- the 50% lethal dose (LD 50 ; mg/kg) was evaluated from the mortality rate (%) observed 14 days after the administration of the compound.
- the mice took diet and drank water freely during the test.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A tetrazoleacetic acid derivative represented by the following general formula (I): ##STR1## .[.[in Formula (I),.]. .Iadd.wherein .Iaddend.R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--.[.].]. except for [5-(2-thienyl)tetrazol-1-yl] acetic acid, [5-(2-furyl)tetrazol-1-yl) acetic acid.Iadd., (5-(5-bromo-2-furyl)tetrazol-1-yl)acetic acid, (5-(5-phenylthio-2-furyl)tetrazol-1-yl)acetic acid, (5-(5-phenylsulfonyl-2-furyl)tetrazol-1-yl)acetic acid .Iaddend.and ethyl esters thereof, or a salt thereof shows excellent aldose reductase inhibitory activity, has low toxicity to organisms and is quite effective as an essential component of a preventative medicine and/or remedy for diabetic complications.
Description
1. Field of the Invention
The present invention relates to a compound having an aldose reductase inhibitory activity and more specifically to a tetrazoleacetic acid derivative and an aldose reductase inhibitor which comprises the tetrazoleacetic acid derivative as an effective component and which is effective as a preventive medicine and/or remedy for diabetic complications as well as a method for alleviating or reducing diabetic complications.
2. Prior Art
It has been known that aldose reductase inhibitors are effective for prevention and/or treatment of diabetic copmplications. This is detailed in the article of Dr. Tsuyoshi TANIMOTO [Division of Biological Chemistry and Reference Standards, National Institute of Hygienic Sciences] (see Farumashia, 1988,24 No. 5, pp. 459-463). This article discloses the chemical structures and 50% inhibitory concentrations (IC50) of representative aldose reductase inhibitors such as Alrestatin, Tolrestat, 4-Isopropyl-BFOC, Sorbinil, M-79175, Alconil, ADN-138, Epalrestat, CT-112 and Statil.
The inventors of this invention already conducted screening of novel aldose reductase inhibitors, found that compounds represented by the following general formula (III): ##STR2## [in Formula (III), R1 represents a hydrogen atom or a group: --A--COOR5 (wherein A represents an alkylene group having 1-4 carbon atoms and R5 represents a hydrogen atom or a lower alkyl group) and R2, R3 and R4 may be the same or different and each represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a phenyl group, a phenoxy group, a nitro group, a residue represented by the formula: NHCO-COOR6 (wherein R6 represents a hydrogen atom or a lower alkyl group) or a residue represented by the following formula: ##STR3## have very high aldose reductase inhibitory activity and already filed a patent application (Japanese Patent Application Serial No. Hei 1-70520).
Among these chemical substances according to the present invention, [5-(2-thienyl)tetrazol-1-yl] acetic acid and ethyl ester thereof as well as [5-(2-furyl)tetrazol-1-yl] acetic acid and ethyl ester thereof are reported in an article of A. K. Zorenzen, Acta Chem. Scand., 1972, 26, p. 541. However, this article only discloses a method for preparing these substances, but there is no disclosure about the biological activity thereof.
Accordingly, an object of the present invention is generally to provide a compound which shows excellent aldose reductase inhibitory activity, has low toxicity to organisms and is quite effective as a preventive medicine and/or remedy for diabetic complications and more specifically to provide a tetrazoleacetic acid derivative.
Another object of the present invention is to provide an aldose reductase inhibitor which comprises the tetrazoleacetic and derivative as an effective component ane which is effective as a preventive medicine and/or remedy for diabetic complications.
A further object of the present invention is to provide a method for alleviating or reducing symptoms related to diabetic complications.
According to an aspect of the present invention, there is provided a novel tetrazoleacetic acid derivative represented by the following general formula (I): ##STR4## [in Formula (I), R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralky group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--] except for [5-(2-thienyl)tetrazol-1-yl] acetic acid, [5-(2-furyl)tetrazol-1-yl] acetic acid.Iadd., (5-(5-bromo-2-furyl)tetrazol-1-yl)acetic acid, (5-(5-phenylthio-2-furyl)tetrazol-1-yl)acetic acid, (5-(5-phenylsulfonyl-2-furyl)tetrazol-1-yl)acetic acid .Iaddend.and ethyl ester thereof or a salt thereof.
According to another aspect of the present invention, there is provided in aldose reductase inhibitor which comrpises a tetrazoleacetic acid derivative represented by the following general formul (II): ##STR5## [in Formula (II), R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--] or a salt thereof and a pharmaceutical acceptable carrier.
According to a further aspect of the present invention, there is provided a method for alleviating or reducing diabetic complications wherein a tetrazoleacetic acid derivative represented by the following general formula (II): ##STR6## [in Formula (II), R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, an aryl group, an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--] or a salt thereof is used.
The tetrazoleacetic acid derivatives and the aldose reductase inhibitor as well as the method for alleviating diabetic complications according to the present invention will hereunder be explained in more detail.
First, each substituent in Formulae (I) or (II) will be explained in detail.
The alkyl group represented by R1 or R2 is, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl group; the aralkyl group includes, for instance, phenylpropyl and benzyl group; examples of the alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and t-butoxy groups; examples of the alkoxyalkyl groups are methoxymethyl and butoxymethyl groups; the haloalkyl groups are, for instance, mono-, di or tri-haloalkyl groups such as chloromethyl, bromomethyl, fluoromethyl and chlorobutyl groups; the alkyl or aryl thio groups are, for instance, methylthio, ethylthio, butylthio and phenylthio groups; the alkylaminosulfonyl groups include, for instance, mono- or dialkylaminosulfonyl groups such as methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl and butylaminosulfonyl groups; the alkyl or aryl sulfonylamino groups are, for instance, methylsulfonylamino, ethylsulfonylamino, butylsulfonylamino and phenylsulfonylamino groups; examples of the alkyl or aryl carbonylamino groups are methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino and phenethylcarbonylamino groups; examples of the alkyl or aryl sulfonyl groups are methylsulfonyl, ethylsulfonyl, butylsulfonyl and piperidinosulfonyl groups; and examples of the alkyl sulfinyl groups are methylsulfinyl, ethylsulfinyl and butylsulfinyl groups. These substituents may be present on any position on the furan or thiophene ring.
In addition, salts of the foregoing compounds represented by Formulae (I) and (II) wherein R1 is a hydrogen atom are pharmaceutically acceptable ones and typical examples thereof include inorganic salts such as alkali metal salts (for instance, sodium salts and potassium salts), alkaline earth metal salts (for instance, calcium salts and magnesium salts) and ammonium salts; and organic salts such as organic amine salts (for instance, triethylamine salts, pyridine salts and ethanolamine salts) and salts with basic amino acids, for instance, arginine.
The aldose reductase inhibitors according to the present invention comprises, as an essential component, at least one compound represented by the foregoing general formula (II) and are effective as preventive medicines and/or remedies for diabetic complications. It has been known that the term "diabetic complications" means a variety of pathema such as peripheral disorder, retinopathy, nephrosis, cataract and keratopathy. These diseases or disorders are triggered by hyperglycemia resulted from the diabetic disease, that the production of sorbitol in the polyol metabolic pathway is correspondingly abnormally accelerated and that, as a result, a large amount of sorbitol is accumulated within cells. This leads to the onset of these diseases.
The aldose reductase inhibitors of the present invention can suppress the sorbitol-pproduction through strong inhibition of the activity of the aldose reductase which catalyzes the sorbitor-production in the foregoing polyol metabolic pathway and thus show excellent preventive and/or treating effects for these various diabetic complications.
The dose of the compounds of formulae (I) and (II) is appropriately determined depending on the conditions or symptoms of patients to be treated, but in general ranges from 1 to 1,000 mg per day for adult which is administered at one time or over several times. The compounds may be administered through any route for medication such as oral administration, subcutaneous injection, intravenous injection and local administration.
The aldose reductase inhibitors of the present invention may usually comprise in addition to the foregoing compounds as the essential components, pharmaceutically acceptable carriers, vehicles and other additives. the inhibitors of the invention may be used in any dosage form such as tablets, powder, fine particles, granules, capsules, pills, liquid preparations, solutions and suspension for injection and eye drops.
Then methods for preparing the compounds (I) as the essential components, conditions therefor or the like will be detailed below with reference to the following reaction schemes. ##STR7##
The reaction scheme I shows the tetrazole ring formation reaction in which N-aryloylaminoalkyl carboxylate is racted with a chlorinating agent such as phosphorus pentoxide, thionyl chloride or thionyl chloride/N,N dimethylformamide to obtain a corresponding imidoyl chloride compound and then the product is reacted with sodium azide to obtain an intended compound of Formula (I). The reaction for obtaining the imidoyl chloride can be carried out in an organic solvent such as benzene, toluene or methylene chloride. In general, the reaction is preferably performed at a temperature of not more than room temperature. In the subsequent cyclization reaction, it is preferred to use soidum azide in an amount of 2 to 6 times that of the imidoyl chloride as an intermediate. The cyclization reaction is in general performed at room temperature in N,N-dimethylformamide.
The reaction scheme 2 means that the compounds of formula (I) in which R1 is a hydrogen atom may be prepared by hydrolysis of the carboxylic acid ester obtained in the reaction scheme 1. The hydrolysis can be performed in the presence of a base such as sodium hydroxide or potassium hydroxide or an acid such as hydrochloric acid. sulfuric acid, acetic acid or trifluoroacetic acid.
The compounds of Formula (I) Prepared according to the foregoing method are separated and purified by a chemical operation commonly employed such as extraction, recrystallization and/or column chromatography and the products thus separated and purified are used as essential components for the aldose reductase inhibitors of the present invention.
The present invention will hereinafter described in more detail with reference to the following non-limitative working Examples and the effects practically achieved by the present invention will also be discussed in detail with reference to Test Examples.
To a solution of 1 g (5.02 mM) of N-(2-thenoyl)glycine methyl ester in 15 ml of anhydrous methylene chloride, there was slowly added 1.5 g (7.2 mM) of phosphorus pentoxide at room temperature with stirring, the resulting mixture was stirred for additional 30 minutes and the reaction solumtion was concentrated at 40° C. under reduced pressure. The resulting residue was dissolved in 5 ml of N,N-dimethylformamide. The solution was dropwose added to a suspension of 1.6 g (24.6 mM) of sodium azide in 3 ml of N,N-dimethylformamide at room temperature over 30 minutes with stirring. After the dropwise addition and agitation for additional 30 minutes at room temperature, the mixture was poured into ice-water and extracted with ethyl acetate. The organic phase obtained was washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resultant residue was subjected to silica gel column chromatography (eluent: ethyl acetate/benzene=1/20) for separation and purification to thus give 0.59 g (yield 52.4%) of methyl (5-(2-thienyl)tetrazol-1-yl] acetate.
M.P.=73-74° C.
N.M.R. (CDCl3) δppm: 3.84 (s, 3H); 5.34 (s, 2H); 7.24 (dd, 1H, J=5.20, 3.60 Hz); 7.58 (dd, 1H, J=3.60, 1.20 Hz); 7.65 (dd, 1H, J=5.20, 1.20 Hz).
I.R. νKBr (cm-1): 3400, 1730, 1650, 1540, 1370, 1230.
Mass: m/z 224 [M+ ]
The following compounds were prepared in the same manner used in Example (1-1)
Starting material: N-(3-methyl-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 2.43 (s, 3H); 3.80 (s, 3H); 5.25 (s, 2H); 7.07 (d, 1H, J=5.0 Hz); 7.52 (d, 1H, J=5.0 Hz).
I.R. νNaCl (cm-1): 3100, 2950, 1760, 1440, 1220, 1000.
Mass: m/z 238 [M+ ]
Starting material: N-(4-methyl-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δpm: 2.34 (s, 3H); 3.83 (s, 3H); 5.33 (s, 2H); 7.22 (d, 1H, J=1.2 Hz); 7.41 (d, 1H, J=1.2 Hz).
I.R. νNaCl (cm-1): 3090, 2950, 1740, 1580, 1440, 1240.
Mass: m/z 238 [M+ ]
Starting material: N (5-methyl-2-thenoyl)glycine methyl ester
M.P.=88-89° C.
N.M.R. (CDCl3) δppm: 2.57 (s, 3H): 3.83 (s, 3H); 5.32 (s, 2H); 6.87˜6.89 (m, 1H); 7.36˜7.39 (m, 1H).
I.R. νKBr (cm-1): 3440, 1750, 1580, 1510, 1430, 1260, 1230, 1100.
Mass: m/z 238 [M+ ]
Starting material: N-(3-thenoyl)glycine methyl ester
M.P.=106-107° C.
N.M.R. (CDCl3) δppm: 3.84 (s, 3H); 5.27 (s, 2H); 7.48 (dd, 1H, J=5.01, 1.20 Hz); 7.56 (dd, 1H, J=5.01, 2.80 Hz); 8.25 (dd, 1H, J=2.80, 1.20 Hz)
I.R. νKBr (cm-1): 3100, 1760, 1580, 1440, 1360, 1230.
Mass m/z 224 [M+ ]
Starting material: N-(2-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.79 (s, 3H); 5.49 (s, 2H); 6.66 (dd, 1H, J=3.60, 2.01 Hz); 7.36 (dd, 1H, J=3.60, 0.80 Hz); 7.64 (dd, 1H, J=2.01, 0.80 Hz)
I.R. νNaCl (cm-1): 3120, 3000, 2950, 1750, 1620, 1520, 1440, 1220, 1010.
Mass: m/z 208 M+ ]
Starting material: N-(3-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.84 (s, 3H); 5.24 (s, 2H); 6.81 (bs, 1H); 7.63 (bs, 1H); 7.96 (bs, 1H)
I.R. νNaCl (cm-1): 3140, 2950, 1750, 1440, 1220.
Mass: m/z 208 [M+ ]
Starting material: N-(5-ethyl-2-thenoyl)glycine methyl ester
M.P.=45-46° C.
N.M.R. (CDCl3) δppm: 1.36 (t, 3H, J=7.70 Hz); 2.91 (dq, 2H, J=7.70, 0.80 Hz); 3.83 (s, 3H); 5.32 (s, 2H); 6.91 (dt, 1H, J=3.60, 0.80 Hz); 7.40 (d, 1H, J=3.60 Hz)
I.R. νKBr (cm-1): 2960, 1760, 1580, 1510, 1430, 1270, 1220, 1100, 1000, 820.
Mass: m/z 252 [M+ ]
Starting material: N-(5-benzyl-2-thenoyl)glycine methyl ester
M.P.=71-72° C.
N.M.R. (CDCl3) δppm: 3.80 (s, 3H); 4.20 (s, 2H); 5.29 (s, 2H); 6.91 (dt, 1H, J=4.01, 1.20 Hz); 7.23˜7.38 (m, 5H); 7.39 (d, 1H, J=4.01 Hz)
I.R. νKBr (cm-1): 3000, 1740, 1580, 1510, 1460, 1420, 1380, 1270, 1240, 800.
Mass: m/z 314 [M+ ]
Starting material: N-(5-methylthio-2-thenoyl)glycine methyl ester
M.P.=64-65° C.
N.M.R. (CDCl3) δppm: 2.60 (s, 3H); 3.84 (s, 3H); 5.31 (S, 2H); 7.07 (d, 1H, J=4.00 Hz); 7.45 (d, 1H, J=4.00 Hz)
I.R. νKBr (cm-1): 3470, 1750, 1580, 1480, 1440, 1410, 1360, 1260, 1220, 1100, 990, 790.
Mass: m/z 270 [M+ ]
Starting material: N-(5-bromo-2-thenoyl)glycine methyl ester
M.P.=45-46° C.
N.M.R. CDCl3) δppm: 3.84 (s, 3H); 5.30 (s, 2H); 7.19 (d, 1H, J=4.90 Hz); 7.30 (d, 1H, J=4.90 Hz)
I.R. νKBr (cm-1): 3450, 1740, 1580, 1490, 1440, 1400, 1270, 1240, 1100, 980, 800.
Mass: m/z 303 [M+ ]
Starting material: N-(2-bromo-3-thenoyl)glycine methyl ester
N.M.R. CDCl3) δppm: 2.58 (s, 3H); 3.80 (s, 3H); 5.12 (s, 2H, 6.99 (d, 1H, J=5.20 Hz); 7.27 (d, 1H, J=5.20 Hz)
I.R. νNaCl (cm-1): 2950, 1750, 1580, 1500, 1440, 1260, 1220.
Mass: m/z 238 [M+ ]
Starting material: N-(5-bromomethyl-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 2.49 (s, 3H); 3.85 (s, 3H); 5.30 (s, 2H); 7.26˜7.36 (m, 2H).
I.R. νNaCl (cm-1): 2950, 1760, 1580, 1500, 1440, 1270, 1220, 1000, 800.
Mass: m/z 317 [M+ ]
Starting material: N-(5-phenyl-2-thenoyl)glycine methyl ester
M.P.=133-134° C.
N.M.R. (CDCl3) δppm 3.85 (s, 3H); 5.38 (s, 2H); 7.39 (d, 1H, J=3.80 Hz); 7.40˜7.48 (m, 3H); 7.55 (d, 1H, J=3.80 Hz); 7.63˜7.66 (m, 2H).
I.R. νKBr (cm-1); 3440, 1760, 1580, 1480, 1420, 1220, 750.
Mass: m/z 300 [M+ ]
Starting material: N-(3-methylcarbonylamino-2-thenoyl)glycine methyl ester
M.P. 35-36° C.
N.M.R. (CDCl3) δppm: 2.31 (s, 3H); 3.84 (s, 3H); 5.45 (s, 2H); 7.56 (d, 1H, J=5.20 Hz); 8.34 (d, 1H, J=5.20 Hz).
I.R. νKBr (cm-1): 3240, 1750, 1580, 1490, 1440, 1220, 1180, 930, 750.
Mass: m/z 281 [M+ ]
Starting material: N-(3-propylcarbonylamino-2-thenoyl)glycine methyl ester
M.P.=92-93° C.
N.M.R. (CDCl3) δppm: 1.04 (t, 3H, J=7.3 Hz); 1.76˜1.90 (m, 2H); 2.51 (t, 3H, J=7.30 Hz); 3.84 (s, 3H); 5.46 (s, 2H); 7.56 (d, 1H, J=5.50 Hz); 8.37 (d, 1H, J=5.50 Hz); 10.75 (bs, 1H).
I.R. νKBr (cm-1): 3270, 2940, 1740, 1680, 1580, 1410, 1380, 1260, 1240, 1100, 760
Mass: m/z 309 [M+ ]
Starting material: N-(3-phenethylcarbonylamino-2-thenoyl)glycine methyl ester
M.P.=96-97° C.
N.M.R. (CDCl3) δppm: 2.85 (t, 2H, J=7.70 Hz); 3.11 (t, 2H, J=7.70 Hz); 3.82 (s, 3H); 5.43 (s, 2H); 7.18˜7.30 (m, 5H); 7.55 (d, 1H, J=5.50 Hz); 8.34 (d, 1H, J=5.50 Hz); 10.75 (bs, 1H).
I.R. νKBr (cm-1): 3300, 1760, 1700, 1580, 1440, 1390, 1220, 1100.
Mass: m/z 371 .[M+ ]
Starting material: N-(5-methyl-2-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 2.39 (d, 3H, J=0.98 Hz); 3.80 (s, 3H); 5.45 (s, 2H); 6.25 (dq, 1H, J=3.66, 0.98 Hz); 7.23 (d, 1H, J=3.66 Hz).
I.R. νNaCl (cm-1): 3120, 2950, 1740, 1620, 1570, 1440, 1220, 1020, 790.
Mass: m/z 222 [M+ ]
Starting material: N-(5-5butyl-2-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 0.95 (t, 3H, J=7.33 Hz); 1.31˜1.45 (m, 2H); 1.57˜170 (m, 2H); 2.70 (t, 2H, J=7.57 Hz); 3.79 (s, 3H); 5.45 (s, 2H); 6.24 (d, 1H, J=3.66 Hz); 7.24 (d, 1H, J=3.66 Hz).
I.R. νNaCl (cm -1): 2950, 1760, 1620, 1560, 1440, 1220, 1020, 790.
Mass m/z 264 [M+ ]
Starting material: N-(5-bromo-2-furoyl)glycine methyl ester
M.P.=106-107° C.
N.M.R. (CDCl3) δppm: 3.84 (s, 3H); 5.45 (s, 2H); 6.58 (d, 1H, J=3.54 Hz); 7.31 (d, 1H, J=3.54 Hz).
I.R. νKBr (cm-1): 3100, 3000, 1730, 1620, 1520, 1440, 1280, 1100, 1000, 780.
Mass: m/z 287 [M+ ]
Starting material: N-(5-methylthio-2-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 2.48 (s, 3H); 3.82 (s, 3H); 5.47 (s, 2H); 6.55 (d, 1H, J=3.66 Hz); 7.32 (d, 1H, J=3.66 Hz).
I.R. νNaCl (cm-1): 3100, 2950, 1750, 1610, 1500, 1440, 1220, 1100, 1010, 780.
Mass: m/z 254 [M+ ]
Starting material: N-(2-bromo-3-furoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.81 (s, 3H); 5.23 (s, 2H);6.70 (d, 1H, J=2.20 Hz); 7.52 (d, 1H, J=2.20 Hz).
I.R. νNaCl (cm-1): 3150, 2950, 1750, 1620, 1530, 1440, 1220, 960.
Mass: m/z 287 .[M+ ]
Starting material: N-[2(-oct-4-yl)-3-furoyl] glycine methyl ester
N.M.R. (CDCl3) δppm: 0.82 (t, 6H, J=7.20 Hz); 1.10˜1.27 (m, 6H): 1.52˜1.70 (m, 4H); 3.25˜3.31 (m, 1H); 3.81 (s, 3H); 5.16 (s, 2H); 6.40 (d, 1H, J=2.20 Hz); 7.48 (d, 1H, J=2.20 Hz).
I.R. νNaCl (cm-1): 2950, 2850, 1750, 1620, 1530, 1440, 1220, 1000, 960.
Mass: m/z 320 [M+ ]
Starting material: N-[2-methylthio-3-furoyl)glycine methyl ester
M.P.=71-72° C.
N.M.R. (CDCl3)δppm: 2.51 (s, 3H); 3.78 (s, 3H); 5.25 (s, 2H); 6.65 (d, 1H, J=2.20 Hz); 7.63 (d, 1H, J=2.20 Hz).
I.R. νNaCl (cm-1): 3150, 2950, 1750, 1600, 1530, 1430, 1220, 960, 740.
Mass: m/z 254 [M+ ]
Starting material: N-(3-methylsulfonylamino-2-thenoyl)glycine methyl ester
M.P.=154-155° C.
N.M.R. (CDCl3) δppm: 3.01 (s, 3H); 3.78 (s, 3H); 5.38 (s, 2H); 7.52 (d, 1H, J=5.61 Hz); 7.55 (d, 1H, J=5.61 Hz); 9.92 (bs, 1H).
I.R. νKBr (cm-1): 3150, 3100, 1740, 1560, 1370, 1220, 1150, 760.
Mass: m/x 317 [M+ ]
Starting material: N-(3-butylsulfonylamino-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 0.87 (t, 3H, J=7.32 Hz); 1.35˜1.44(m, 2H); 1.57˜1.75 (m, 2H); 3.14 (t, 2H, J=7.94 Hz); 3.84 (s, 3H); 5.45 (s, 2H); 7.54 (d, 1H, J=5.49 Hz); 7.62 (d, 1H, J=5.49 Hz); 9.98 (bs, 1H).
I.R. νNaCl (cm-1): 3100, 1750, 1560, 1370, 1220, 1150
Mass: m/z 359 [M+ ]
Starting material: N-(3-phenylsulfonylamino-2-thenoyl)glycine methyl ester
M.P.=124-125° C.
N.M.R. (CDCl3) δppm: 3.72 (s, 3H); 5.23 (s, 2H); 7.31˜7.47 (m, 5H); 7.53 (d, 1H, J=5.62 Hz); 7.58˜7.91 (m, 2H); 10.16 (bs, 1H).
I.R. νKBr (cm-1): 3120, 2950, 1750, 1560, 1520, 1430, 1380, 1240, 1160, 760, 580.
Mass: m/z 379 [M+ ]
Starting material: N-(2-methyl-3-furoyl)glycine methyl ester
M.P.=54.5-56° C.
N.M.R. (CDCl3) δppm: 2.58 (s, 3H); 3.82 (s, 3H); 5.19 (s, 2H); 6.44 (d, 1H, J=2.00 Hz); 7.45 (d, 1H, J=2.00 Hz).
I.R. νKBr (cm-1): 3410, 3150, 1760, 1620, 1540, 1460, 1370, 1230.
Mass: m/z 222 [M+ ]
Starting material: N-[5- [N'-methyl-N'- [2-(methoxymethoxy)ethyl]-aminosulfonyl]-2-thienoyl)] glycine methyl ester
N.M.R. (CDCl3) δppm: 2.77 (s, 3H); 3.14 (t, 2H, J=5.37 Hz); 3.32 (s, 3H); 3.59 (t, 2H, J=5.37 Hz); 3.72 (s, 3H); 4.56 (s, 2H; 5.21 (s, 2H); 7.25 (d, 1H, J=5.13 Hz); 7.71 (d, 1H, J=5.13 Hz).
I.R. νKBr (cm-1): 2950, 1750, 1440, 1350, 1220, 1150, 1040, 750, 710.
Mass: m/z 405 [M+ ]
0.5 g (2.2 mM) of methyl [5-(2-thienyl)tetrazol-1-yl) acetate obtained in Example (1-1) was dissolved in 3 ml of methanol, 1 ml of a 4 N aqueous sodium hydroxide solution was added to the resulting solution at room temperature and the mixture was refluxed with heating for one hour. After cooling the mixture to room temperature, it was diluted with water, then impurities were removed with ethyl acetate and the aqueous phase was separated. The aqueous phase was acidified with hydrochloric acid, crystals precipitated out were filtered off, washed with water and recrystallized from a 50% ethanol-water mixture to give 0.39 g (yield 84.4%) of [5-(2-thienyl)tetrazol-1-yl] acetic acid.
M.P.=129-130° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 4.9˜6.2 (br, 1H); 5.30 (s, 3H); 7.27˜7.33 (m, 1H); 7.61 (dd, 1H, J=3.60, 1.20 Hz): 7.68 (dd, 1H, J=3.60, 1.20 Hz).
I.R. νKBr (cm-1): 3380, 1730, 1580, 1350, 1250.
Mass: m/z 210 [M+ ]
The following compounds were prepared in the same manner used in Example (2-1)
Starting Material: methyl [5-(3-methyl-2-thienyl)tetrazol-1-yl] acetate
M.P.=165-166° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.42 (s, 3H); 3.70 (bs, 1H); 5.20 (s, 2H); 7.06 (d, 1H, J=5.2 Hz); 7.53 (d, 1H, J=5.2 Hz).
I.R. νKBr (cm-1): 3100, 2500, 1720, 1570, 1510, 1420, 1220.
Mass: m/z 224 [M+ ]
Starting Material: methyl [5-(4-methyl-2-thienyl)tetrazol-1-yl] acetate
M.P.=154-155° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.34 (s, 3H); 5.29 (bs, 3H); 7.22 (d, 1H, J=1.2 Hz); 7.41 (d, 1H, J=1.2 Hz).
I.R. νKBr (cm-1): 3500, 2550, 1730, 1520, 1450, 1270, 1240, 1120.
Mass: m/z 224 [M+ ]
Starting Material: methyl. [5-(5-methyl-2-thienyl)tetrazol-1-yl] acetate
M.P.=150-151° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.58 (s, 3H); 5.28 (s, 2H); 5.90 (bs, 1H); 6.88˜6.92 (m, 1H); 7.39˜7.42 (m, 1H).
I.R. νKBr (cm-1): 3400, 2990, 1730, 1580, 1520, 1440, 1260, 1240, 1000.
Mass: m/z 224 [M+ ]
Starting Material: methyl [5-(3-thienyl)tetrazol-1-yl] acetate
M.P.=172-173° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 3.33 (bs, 1H); 5.58 (s, 2H); 7.57-(dd, 1H, J=5.20, 1.20 Hz); 7.85 (dd, 1H, J=5.20, 2.80 Hz); 8.25 (dd, 1H, J=2.80, 1.20 Hz).
I.R. νKBr (cm-1): 3380, 3120, 1730, 1580, 1280.
Mass: m/z 210 [M+ ]
Starting Material: methyl [5-(2-furyl)tetrazol-1-yl] acetate
M.P.=157-158° C. (decomposition)
N.M.R. (CDCl3 -DMSO-d6) δppm: 4.79 (bs, 1H); 5.45 (s, 2H); 6.81 (dd, 1H, J=3.60, 1.60 Hz); 7.37 (d, 1H, J=3.6 Hz); 8.08 (d, 1H, J=1.70 Hz).
I.R. νKBr (cm-1): 3010, 2970, 2520, 1730, 1620, 1520, 1220, 1020.
Mass: m/z 194 [M+ ]
Starting Material: methyl [5-(3-furyl)tetrazol-1-yl] acetate
M.P.=150-151° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 3.33 (bs, 1H); 5.56 (s, 2H); 7.00 (bs, 1); 7.97 (bs, 1H); 8.46 (bs, 1H).
I.R. νKbr (cm-1): 3370, 2430, 1720, 1620, 1350, 1240.
Mass: m/z 194 [M+ ]
Starting Material: methyl [5-(5-ethyl 2-thienyl)tetrazol-1-yl] acetate
M.P.=131-138° C.
N.M.R. (DMSO-d6) δppm: 1.36 (dt, 3H, J=7.70, 1.20 Hz); 2.93 (q, 2H, J=7.70 Hz); 3.28 (bs, 1H); 5.28 (s, 2H); 6.92 (dd, 1H, J=3.60, 1.20 Hz); 7.41 (dd, 1H, J=3.60, 1.20 Hz).
I.R. νKBr (cm-1): 3490, 2950, 1740, 1580, 1500, 1410, 1220, 1110, 800.
Mass m/z 238 . [M+ ]
Starting Material: methyl [5-(5-benzyl-2-thienyl)tetrazol-1-yl] acetate
M.P.=148-149° C.
N.M.R. (DMSO-d6) δppm: 4.02 (s, 2H); 4.70 (bs, 1H); 5.25 (s, 2H); 6.92 (dd, 1H, J=3.60, 0.80 Hz); 7.23˜7.38 (m, 5H); 7.41 (d, 1H, J=3.60).
I.R. (cm-1): 2950, 1750, 1580, 1510, 1430, 1230.
Mass: m/z 300 [M+ ]
Starting Material: methyl [5-(5-methylthio-2-thienyl)tetrazol-1-yl ] acetate
M.P.=179° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.61 (s, 3H); 5.34 (s, 2H); 7.10 (d, 1H, J=4.01 Hz); 7.49 (d, 1H, J=4.01 Hz).
I.R. νKBr (cm-1): 3400, 1730, 1570, 1480, 1410, 1210.
Mass: m/z 256 [M+ ]
Starting Material: methyl. [5-(5-bromo-2-thienyl)tetrazol-1-yl] acetate
M.P.=200° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 5.30 (s, 2H); 6.63 (bs, 1H); 7.19 (d, 1H, J=4.01 Hz); 7.34 (d, 1H, J=4.01 Hz).
I.R. νKBr (cm-1): 3100, 2900, 1730, 1580, 1490, 1440, 1400, 1280, 1260, 1100, 980, 880. 800.
Mass: m/z 289 [M+ ]
Starting Material: methyl [5-(2-methyl-3-thienyl)tetrazol1-yl] acetate
M.P.=144° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.57 (s, 3H); 5.08 (s, 2H); 7.06 (d, 1H, J=5.20 Hz); 7.27 (d, 1H, J=5.20 Hz).
I.R. νKBr (cm-1): 2900, 1740, 1570, 1440, 1400, 1340, 1260, 1220.
Mass: m/z 224 [M+ ]
Starting Material: methyl [5-(5-bromomethyl-2-thienyl)tetrazol-1-yl] acetate
M.P.=192° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.49 (s, 3H); 4.62 (bs, 1H); 5.28 (s, 2H); 7.39˜7.41 (m, 2H).
I.R. νKBr (cm-1): 3000, 1740, 1500, 1240, 1140.
Mass: m/z 303 [M+ ]
Starting Material: methyl [5-(5-phenyl-2-thienyl)tetrazol-1-yl] acetate
M.P.: 210° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 4.03 (bs, 1H); 5.36 (s, 2H) 7.36˜7.48 (m, 3H); 7.42 (d, 1H, J=4.01 Hz); 7.58 (d, 1H, J=4.01 Hz); 7.64˜7.67 (m, 2H).
I.R. νKBr (cm-1): 3000, 1730, 1580, 1480, 1430, 1240, 1110, 760.
Mass: m/z 286 [M+ ]
Starting Material: methyl [5-(3-methoxy-2-thienyl)tetrazol-1-yl] acetate
M.P.: 234° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 3.94 (s, 3H); 5.36 (s, 2H); 6.95 (d, 1H, J=5.50 Hz); 7.55 (d, 1H, J=5.50 Hz).
I.R. νKBr (cm-1): 3110, 2950, 1740, 1580, 1520, 1440, 1250, 1200, 1070, 800, 750.
Mass: m/z 240 [M+ ]
Starting Material: methyl [5-(3-butoxy-2-thienyl)tetrazol-1-yl] acetate
M.P.: 197-198° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 0.95 (t, 3H, J=7.30 Hz); 1.34˜1.41 (m, 2H); 1.70˜1.81 (m, 2H); 4.13 (t, 2H, J=6.60 Hz); 4.80 (bs, 1H); 5.35 (s, 2H); 6.94 (d, 1H, J=5.50 Hz); 7.54 (d, 1H, J=5.50 Hz).
I.R. νKBr (cm-1): 3500, 2950, 1730, 1570, 1510, 1400, 1250, 1200, 1070, 800, 750.
Mass: m/s 282 [M+ ]
Starting Material: methyl [5-(3-methylcarbonylamino-2-thienyl)-tetrazol-1-yl] acetate
M.P.: 221° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.92 (s, 3H); 3.80˜4.80 (br, 1H); 5.42 (s, 2H); 7.59 (d, 1H, J=5.40 Hz); 8.28 (d, 1H, J=5.40 Hz).
I.R. νKBr (cm-1): 3250, 2920, 1740, 1650, 1580, 1440, 1390, 1240, 1220, 1110, 760.
Mass: m/z 267 [M+ ]
Starting Material: methyl [5-(3-propylcarbonylamino 2-thienyl)-tetrazol-1-yl] acetate
M.P.: 192° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 1.03 (t, 3H, J=7.30 Hz); 1.74˜1.88 (m, 2H); 2.19 (t, 2H, J=7.30 Hz); 4.40˜5.60 (br, 1H); 5.41 (s, 2H); 7.59 (d, 1H, J=5.50 Hz); 8.30 (d, 1H, J=5.50 Hz); 10.74 (bs, 1H).
I.R. νKBr (cm-1): 3310, 2960, 1720, 1590, 1530, 1440, 1180, 760.
Mass: m/z 295 [M+ ]
Starting Material: methyl [5-(3-phenethylcarbonylamino-2-thienyl) tetrazol-1-yl] acetate
M.P.: 178° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.83 (t, 2H, J=7.70 Hz); 3.09 (t, 2H, J=7.70 Hz); 4.22 (bs, 1H); 5.39 (s, 2H); 7.18˜7.30 (m, 5H); 7.60 (d, 1H, J=5.50 Hz); 8.27 (d, 1H, J=5.50 Hz); 10.72 (bs, 1H).
I.R. νKBr (cm-1); 3450, 2920, 1740, 1640, 1580, 1440, 1400, 1220, 1110.
Mass: m/z 357 [M+ ]
Starting Material: methyl [5-(5-butyl-2-thienyl)tetrazol-1-yl] acetate
M.P.: 103-104° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 0.95 (t, 3H, J=7.33 Hz); 1.35˜1.49 (m, 2H); 1.65˜1.76 (m, 2H); 2.89 (t, 2H, J=7.33 Hz); 5.27 (s, 2H); 6.89 (d, 1H, J=3.66 Hz); 7.41 (d, 1H, J=3.66 Hz).
I.R. νKBr (cm-1): 2920, 1730, 1580, 1520, 1420, 1220, 800.
Mass: m/z 266 [M+ ]
Starting Material: methyl [5-(5-phenylpropyl 2-thienyl)-tetrazol-1-yl] acetate
M.P.: 85-86° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 2.06 (quint., 2H, J=7.57 Hz); 2.71 (t, 2H, J=7.57 Hz); 2.91 (t, 2H, J=7.57 Hz); 4.98 (bs, 1H; 5.28 (s, 2H); 6.91 (d, 1H, J=3.80 Hz); 7.18˜7.33 m, 5H); 7.42 (d, 1H, J=3.80 Hz).
I.R. νKBr (cm-1): 2920, 1720, 1580, 1510, 1420, 1220, 1130, 800.
Mass: m/z 328 [M+ ]
Starting Material: methyl [5-(5-methoxymethyl-2-thienyl)-tetrazol-1-yl] acetate
M.P.: 124-125° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 3.43 (s, 3H); 4.67 (d, 2H, J=0.73 Hz); 5.29 (s, 2H); 7.10 (dt, 1H, J=3.66, 0.73 Hz); 7.49 (d, 1H, J=3.66 Hz).
I.R. νKBr (cm-1): 2900, 1740, 1580, 1420, 1220, 1020, 800.
Mass: m/z 254 [M+ ]
Starting Material: methyl [5-(5-butoxymethyl-2-thienyl)-tetrazol-1-yl] acetate
M.P.: 67-68° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 0.93 (t, 3H, J=7.20 Hz); 1.38˜1.47 (m, 2H); 1.55˜1.66 (m, 2H); 3.54 (t, 2H, J=6.47 Hz); 4.67 (d, 2H, J=0.73 Hz); 4.07 (s, 2H); 5.27 (s, 2H); 7.07 (d, 1H, J=3.79 Hz); 7.47 (d, 1H, J=3.79 Hz).
I.R. νKBr (cm-1): 2950, 1730, 1580, 1420, 1230, 1090, 800.
Mass: m/z 296 [M+ ]
Starting Material: methyl [5-(2-bromo-3-thienyl)tetrazol-1-yl] acetate
M.P.: 145-146° C.
N.M.R. (CDCl3 +DMSO-d 6) δppm: 4.56 (bs, 1H); 5.10 (s, 2H); 7.12 (d, 1H, J=5.18 Hz); 7.47 (d, 1H, J=5.18 Hz).
I.R. νKBr (cm-1): 2950, 1740, 1570, 1440, 1220, 1000, 800, 720.
Mass: m/z 289 [M+ ]
Starting Material: methyl [5-[2-(oct-4-yl)-3-thienyl] tetrazol-1-yl] acetate
M.P.: 79-80° C.
N.M.R. (CDCl3 +DMSO-d 6) δppm: 0.78˜0.84 (m, 6H); 1.13˜1.25 (m, 6H); 1.45˜1.71 (m, 4H); 3.15˜3.22 (m, 1H); 5.00 (s, 2H); 7.01 (d, 1H, J=5.37 Hz); 7.36 (dd. 1H, J=5.37, 0.73 Hz).
I.R. νKBr (cm-1): 2900, 1740, 1570, 1110, 1220, 720.
Mass: m/z 322 . [M+ ]
Starting Material: methyl [5-(2-methylthio-3-thienyl)-tetrazol-1-yl] acetate
M.P.: 134-135° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 2.51 (s, 3H); 5.14 (s, 2H); 7.18 (d, 1H, J=5.50 Hz); 7.47 (d, 1H, J=5.50 Hz).
I.R. νKBr (cm-1): 3100, 2900, 1730, 1550, 1440, 1220, 800,
Mass: m/z 256 [M+ ]
Starting Material: methyl [5-(5-methyl-2-furyl)tetrazol-1-yl] acetate
M.P. 150-151° C. (decomposition)
N.M.R. (CDCl3 +DMSO-d6) δppm: 2.41 (s, 3H); 5.40 (s, 2H); 6.23 (dd, 1H, J=3.42, 0.98 Hz); 7.20 (d, 1H, J=3.42 Hz).
I.R. νKbr (cm-1): 3500, 3100, 1720, 1570, 1440, 1240, 800.
Mass: m/z 208 [M+ ]
Starting Material: methyl. [5-(5-butyl-2-furyl)tetrazol-1-yl] acetate
M.P.: 109-110° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 0.95 (t, 3H, J=7.20 Hz); 1.32˜1.46 (m, 2H); 1.62˜1.73 (m, 2H); 2.72 (t, 2H, J=7.56 Hz); 5.40 (s, 2H); 6.24 (d, 1H, J=3.42 Hz); 7.19 (d, 1H, J=3.42 Hz).
I.R. νKBr (cm-1): 2900, 1740, 1560, 1450, 1200, 800.
Mass: m/z 250 [M+ ]
Starting Material: methyl [5-(5-bromo-2-furyl)tetrazol-1-yl] acetate
M.P.: 159-160° C. (decomposition)
N.M.R. (CDCl3 +DMSO-d6) δppm: 5.41 (s, 2H); 6.60 (d, 1H, J=3.66 Hz); 7.27 (d, 1H, J=3.66 Hz).
I.R. νKBr (cm-1): 3150, 3000, 1730, 1600, 1420, 1200, 740.
Mass: m/z 273 [M+ ]
Starting material: methyl [5-(5-methylthio-2-furyl)tetrazol-1-yl] acetate
M.P.: 160.5-161.5° C. (decomposition)
N.M.R. (CDCl3 +DMSO-d6) δppm: 2.51 (s, 3H); 5.43 (s, 2H); 6.55 (d, 1H, J=3.66 Hz); 7.28 (d, 1H, J=3.66 Hz).
I.R. νKBr(cm-): 3100, 3000, 1730, 1620, 1500, 1440, 1210, 1200, 800.
Mass: m/z 240 [M+ ]
Starting Material: methyl [5-(2-bromo-3-furyl)tetrazol-1-yl] acetate
M.P.: 138-139° C. (decomposition)
I.R. (CDCl3 +DMSO-d6) δppm: 5.17 (s, 2H); 4.33 (bs, 1H); 6.74 (d, 1H, J=2.20 Hz); 7.54 (d, 1H, J=2.20 Hz).
I.R. νKBr (cm-1): 3100, 3000, 1720, 1620, 1520, 1440, 1260, 1100, 1010, 930
Mass m/z 273 [M+ ]
Starting Material: methyl [5-(2-methylthio-3-furyl)tetrazol-1-yl] acetate
M.P.: 120-122° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 2.53 (s, 3H); 4.09˜4.65 (br, 1H); 5.43 (s, 3H); 6.71 (d, 1H, J=1.95 Hz); 7.67 (d, 1H, J=1.95 Hz).
I.R. νKBr (cm-1): 3300, 3150, 2950, 1730, 1590, 1440, 1220, 960, 810, 740.
Mass: m/z 240 [M+ ]
Starting Material: methyl [5-(2-phenylthio-3-thienyl)tetrazol-1-yl] acetate
M.P.: 133-134° C. (decomposition)
N.M.R. (CDCl3 +DMSO-d 6) δppm: 5.50 (s, 2H); 7.23˜7.29 (m, 6H); 7.59 (d, 1H, J=5.30 Hz).
I.R. νKBr (cm-1): 3100, 3000, 1720, 1570, 1480, 1430, 1390, 1260, 870, 730.
Mass: m/z 318 [M+ ]
(2-34) [5-(5-phenylthio-2-thienyl)tetrazol-1-yl ] acetic acid (yield=61.0%)
Starting Material: methyl [5-(5-phenylthio-2-thienyl)tetrazol-1-yl] acetate
M.P.: 125-126° C. (decomposition)
N.M.R. (CDCl3 +DMSO-d6) δppm: 3.37 (bs, 1H); 5.29 (s, 2H); 7.27˜7.38 (m, 6H); 7.51 (d, 1H, J=3.90 Hz).
I.R. νKBr (cm-1): 3000, 1730, 1580, 1480, 1430, 1410, 1220, 1130, 800, 730.
Mass m/z 318 [M+ ]
Starting Material: methyl [5- [5-(N,N-diethylaminosulfonyl)-2-thienyl] tetrazol-1-yl ] acetate
M.P.: 134-135° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 1.01 (t, 6H, J=7.08 Hz); 3.10 (q, 4H, J=7.08 Hz); 3.32 (bs, 1H); 5.25 (s, 2H); 7.23 (d, 1H, J=5.13 Hz); 8.18 (d, 1H, J=5.13 Hz).
I.R. νKBr (cm-1): 3100, 2970, 1740, 1410, 1360, 1220, 1150, 940, 700, 590.
Mass: m/z 333 [m+ ]
Starting Material: methyl [5-[5-(N,N-dibutylaminosulfonyl)-2-thienyl] tetrazol-1-yl] acetate
N.M.R. (CDCl3) δpmm: 0.79 (t, 6H, J=7.32 Hz); 1.09˜1.23 (m, 4H); 1.30˜1.41 (m, 4H); 2.87 (t, 4H), J=7.57 Hz); 5.14 (s, 2H); 7.11 (d, 1H, J=5.12 Hz); 7.61 (d, 1H, J=5.12 Hz).
I.R. νNaCl (cm-1): 2950, 1740, 1340, 1220, 1150.
Mass: m/z 401 [M+ ]
Starting Material: methyl [5-(5-piperidinosulfonyl-2-thienyl)-tetrazol-1-yl ] acetate
M.P.: 143-146° C.
N.M.R. (CDCl3) δppm: 1.38˜1.39 (m, 2H); 1.48˜1.58 (m, 4H); 2.86 (t, 4H, J=5.37 Hz); 5.15 (s, 2H); 7.16 (d, 1H, J=5.13 Hz); 7.66 (d, 1H, J=5.13 Hz).
I.R. νKbr (cm-1): 3450, 2950, 1735, 1340, 1230, 1160.
Mass: m/z 357 [M+ ]
Starting Material: methyl [5- [2-(N,N-diethylaminosulfonyl)-5-trimethylsilyl-3-thienyl] tetrazol-1-yl] acetate
M.P.: 128.5-130° C.
N.M.R. (CDCl3) δppm: 1.00 (t, 6H, J=7.08 Hz); 3.00 (q, 4H, J=7.08 Hz): 5.13 (s, 2H); 7.10 (d, 1H, J=4.88 Hz); 7.62 (d, 1H, J=4.88 Hz).
I.R. νKBr (cm-1): 2950, 1740, 1340, 1220, 1140.
Mass: m/z 331 [M+ ]
Starting Material: methyl [5-(3-methylsulfonylamino-2-thienyl) tetrazol-1-yl] acetate
M.P.: 154-155° C.
N.M.R. (CDCl3) δppm: 3.01 (s, 3H); 3.78 (s, 3H); 5.38 (s, 2H); 7.53 (d, 1H, J=5.61 Hz); 7.62 (d, 1H, J=5.61 Hz); 9.92 (bs, 1H).
I.R. νKBr (cm-1): 3150. 3100, 1740, 1560, 1370, 1330, 1220, 1150, 760.
Mass: m/z 303 [M+ ]
Starting Material: methyl [5-(3-butylsulfonylamino-2-thienyl) tetrazol-1-yl] acetate
M.P.: 158-159° C. (decomposition)
N.M.R. (CDCl3) δppm: 0.87 (t, 2H, J=7.32 Hz); 1.35˜1.44 (m, 2H); 1.75˜1.85 (m, 2H); 3.14 (t, 2H, J=7.95 Hz); 3.84 (s, 3H); 5.45 (s, 2H); 7.54 (d, 1H, J=5.49 Hz); 7.62 (d, 1H, J=5.49 Hz); 9.98 (bs, 1H).
I.R. νKBr (cm-1): 3100, 2950, 1750, 1560, 1370, 1220, 1150.
Mass: m/z 345 [M+ ]
Starting Material: methyl [5-(3-phenylsulfonylamino)-2-thienyl) tetrazol-1-yl] acetate
M.P.: 124-125° C.
N.M.R. (CDCl3) δppm: 3.72 (s, 3H); 5.23 (s, 2H); 7.31˜7.17 (m, 5H); 7.53 (d, 1H, J=5.62 Hz); 7.58˜7.91 (m, 2H): 10.16 (bs, 1H).
I.R. νKBr (cm-1): 3120, 2950, 1750, 1560, 1520, 1430. 1380, 1240, 1160, 760, 580.
Mass: m/z 365 [M+ ]
Starting Material: methyl [5-(3-hydroxy-2-thienyl)tetrazol-1-yl] acetate
M.P.: 199-200° C. (decomposition)
N.M.R. (CDCl3) δppm: 4.36 (bs, 1H); 5.38 (s, 2H); 6.87 (d, 1H, J=5.37 Hz); 7.45 (d, 1H, J=5.37 Hz); 10.23 (bs, 1H).
I.R. νKBr (cm-1): 3450, 2850, 1720, 1440, 1230, 1120, 1010, 750. Mass: m/z 226 [M+ ]
Starting Material: methyl [5-(2-methylsulfinyl-3-thienyl)-tetrazol-1-yl] acetate
M.P.: 144-145° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 3.08 (s, 3H): 5.15 (d, 1H, J=17.82 Hz); 5.30 (d, 1H, J=17.82 Hz); 7.34 (d, 1H, J=5.12 Hz); 7.81 (d, 1H, J=5.12 Hz).
I.R. νKBr (cm-1): 3100, 2900, 1700, 1570, 1420, 1300, 1260, 1220, 1000, 760.
Mass: m/z 272 [M+ ]
Starting Material: methyl [5-(2-methylsulfonyl-3-thienyl)-tetrazol-1-yl ] acetate
M.P.: 135-136° C.
N.M.R. (CDCl3 +DMSO-d6) δppm: 3.32 (bs, 1H); 3.48 (s, 3H); 5.37 (s, 2H); 7.40 (d, 1H, J=5.13 Hz); 8.32 (d, 1H, J=5.13 Hz).
I.R. νKBr (cm-1): 3500, 3100, 3000, 1720, 1310, 1140, 950, 760.
Mass: m/z 288 [M+ ]
Starting Material: methyl [5-(3-methylcarbonylamino 2-thienyl)-tetrazol-1-yl] acetate
M.P.: 258° C. (decomposition)
N.M.R. (DMSO-d6) δppm: 2.34 (bs, 1H); 5.17 (s, 2H); 7.02 (d, 1H, J=5.50 Hz); 7.59 (d, 1H, J=5.50 Hz); 11.01 (bs, 1H).
I.R. νKBr (cm-1): 3240, 3160, 1700, 1590, 1530, 1380, 1040, 770.
Starting Material: methyl [5- [5- [N-methyl-N- [2-(methoxyethoxy)-ethyl] aminosulfonyl]-2-thienyl] -tetrazol-1-yl] acetate
N.M.R. (CD3 OD) δppm: 2.77 (s, 3H); 3.07 (t, 2H, J=5.61 Hz); 3.60 (t, 2H, J=5.61 Hz); 5.24 (s, 2H); 7.26 (d, 1H, J=5.13 Hz); 8.02 (d, 1H, J=5.13 Hz).
I.R. νNaCl (cm-1): 3450, 2950, 1740, 1440, 1350, 1150, 1040, 590.
Mass: m/z 347 [M+ ]
To a solution of 500 mg (2.51 mM) of N-(2-thenoyl)glycine methyl ester in 5 ml of anhydrous methylene chloride, there were added, at room temperature, 185 mg (2.53 mM) of anhydrous N,N-dimethylformamide and 418 mg (3.51 mM) of thionyl chloride and then the mixture was refluxed for one hour. The reaction solution was concentrated at 40° c. under reduced pressure and the resulting residue was dissolved in 5 m l of anhydrous N,N-dimethylformamide.
The resulting solution was dropwise added to a suspension of 410 mg (6.3 mM) of sodium azide in 3 ml of anhydrous N,N dimethylformide at a temperature of the suspension ranging from 5° to 10° C. over 30 minutes with stirring. After the dropwise addition, the reaction mixture was stirred for additional 30 minutes at room temperature, poured into ice-water and extracted with ethyl acetate. The organic phase obtained was washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resultant residue was recrystallized from ethyl acetate/n hexane to give 395 mg (yield 70.2%) of methyl [5-(2-thienyl)tetrazol-1-yl] acetate.
The results of the instrumental analysis of the product are consistent with those for the product obtained in Example (1-1).
To a solution of 1 g (4.69 mM) of N-(3-thenoyl)glycine methyl ester in 10 ml of anhydrous methylene chloride, there were added, at room temperature, 350 mg (4.79 mM) of anhydrous N,N-dimethylformamide and 800 mg (6.72 mM) of thionyl chloride and then the mixture was refluxed for one hour. The reaction solution was concentrated at 40° C. under reduced pressure and the resulting residue was dissolved in 10 ml of anhydrous N,N-dimethylformamide.
the resulting solution was dropwise added to a suspension of 800 mg (12.3 mM) of sodium azide in 5 ml of anhydrous N,N-dimethylformamide as a temperature of the suspension ranging from 5° to 10° C. over 30 minutes and stirring. After the dropwise addition, the reaction mixture was stirred for additional 30 minutes at room temperature, poured into ice-water and extracted with ethyl acetate. The organic phase obtained was washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The resultant residue was recrystallized from ethyl acetate/n hexane to give 730 mg (yield 65.3%) of ethyl [5-(3-thienyl)tetrazol-1-yl] acetate.
M.P.: 69.5-70.5° C.
N.M.R. (CDCl3) δppm: 1.27 (t, 3H, J=7.25 Hz); 4.26 (g, 2H, J=7.25 Hz); 5.25 (s, 2H); 7.48 (dd, 1H, J=5.20, 1.21 Hz); 7.55 (dd, 1H, J=5.20, 2.82 Hz); 7.84 (dd, 1H, J=2.82, 1.21 Hz).
I.R. νKbr (cm-1): 3100, 2970, 2950, 1740, 1570, 1440, 1370, 1210, 880.
Mass: m/z 238 [M+ ]
The following compounds were prepared in the same manner as described above.
Starting Material: N-(3-methoxy-2-thenoyl)glycine methyl ester
M.P.: 121-122° C.
N.M.R. (CDCl3) δppm: 3.76 (s, 3H); 3.90 (s, 3H); 5.34 (s, 2H); 6.97 (d, 1H, J=5.64 Hz); 7.54 (d, 1H, J=5.64 Hz).
I.R. νKBr (cm-1): 3100, 2950, 1760, 1580, 1520, 1400, 1240, 1220, 1070, 760.
Mass: m/z 254 [M+ ]
Starting Material: N-(3-butoxy-2-thenoyl)glycine methyl ester
M.P.: 62-62.5° C.
N.M.R. (CDCl3) δppm: 0.88 (t, 3H, J=7.26 Hz); 1.28˜1.39 (m, 2H); 1.59˜1.70 (m, 2H); 3.66 (s, 3H); 4.04 (t, 2H, J=6.85 Hz); 5.34 (s, 2H); 6.84 (d, 1H, J=5.64 Hz); 7.45 (d, 1H, J=5.64 Hz).
I.R. νKBr (cm-1); 3100, 2950, 1760, 1580, 1510, 1400, 1240, 1220, 1050, 750.
Mass: m/z 296 [M+ ]
Starting Material: N-(5-butyl-2-thenoyl)glycine methyl ester
M.P.: 58-59° C.
N.M.R. (CDCl3) δppm: 0.95 (t, 3H, J=7.32 Hz); 1.37˜1.46 (m, 2H); 1.65˜1.76 (m, 2H); 2.88 (t, 2H, J=7.32 Hz); 3.83 (s, 3H); 5.32 (s, 2H); 6.89 (d, 1H, J=3.66 Hz); 7.38 (d, 1H, J=3.66 Hz).
I.R. νKBr (cm-1): 2950, 1740, 1580, 1520, 1440, 1380, 1220, 1100, 1000, 800.
Mass m/z 280 [M+ ]
Starting Material: N-(5-phenylpropyl-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 2.06 (quint., 2H, J=7.57 Hz); 2.71 (t, 2H, J=7.57 Hz); 2.91 (t, 2H, J=7.57 Hz); 3.83 (s, 3H); 5.31 (s, 2H); 6.90 (dt, 1H, J=3.72 0.73 Hz); 7.18˜7.34 (m, 5H); 7.40 (d, 1H, J=3.72 Hz).
I.R. νNaCl (cm-1): 2920, 1750, 1580. 1500, 1440, 1220, 1100, 700.
Mass: m/z 342 [M+ ]
Starting Material: N-(5-methoxymethyl-2-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.44 (s, 3H); 3.84 (s, 3H); 4.67 (d, 2H, J=0.73 Hz); 5.33 (s, 2H); 7.10 (dt, 1H, J=3.66, 0.73 Hz); 7.48 (d, 1H, J=3.66 Hz).
I.R. νNaCl (cm-1): 2950, 1750, 1580, 1440, 1360, 1220, 1000, 800.
Mass: m/z 268 [M+ ]
Starting Material: N-(5-butoxymethyl-2-thenoyl)glycine methyl ester
M.P.: 48-49° C.
N.M.R. (CDCl3) δppm: 0.93 (t, 3H, J=7.21 Hz); 1.33˜1.45 (m, 2H); 1.56˜1.66 (m, 2H); 3.54 (t, 2H, J=6.74 Hz); 3.83 (s, 3H); 4.70 (d, 2H, J=0.73 Hz); 5.33 (s, 2H); 7.07 (dt, 1H, J=3.72, 0.73 Hz); 7.46 (d, 1H, J=3.72 Hz).
I.R. νKBr (cm-1): 2950, 2850, 1740, 1580, 1420, 1230, 1100, 800.
Mass: m/z 310 [M+ ]
Starting Material: N-(2-bromo-3-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.76 (s, 3H); 5.17 (s, 2H); 7.10 (d, 1H, J=5.73 Hz); 7.48 (d, 1H, J=5.73 Hz).
I.R. νNaCl (cm-1): 3100, 2950, 1750, 1580, 1430, 1220, 1000
Mass: m/z 303 [M+ ]
Starting Material: N- [2- (oct-4-yl)-3-thenoyl] glycine methyl ester
N.M.R. (CDCl3) δppm: 0.78˜0.85 (m, 6H); 1.11˜1.26 (m, 6H); 1.50˜1.67 (m, 4H); 3.12˜3.18 (m, 1H); 3.81 (s, 3H); 5.05 (s, 2H); 6.93 (d, 1H, J=5.37 Hz); 7.36 (d, 1H, J=5.37 Hz).
I.R. νNaCl (cm-1): 2950, 2850, 1760, 1440, 1220.
Mass: m/z 336 [M+ ]
Starting Material: N-)2-methylthio-3-thenoyl)glycine methyl ester
M.P. 90-91° C.
N.M.R. (CDCl3) δppm: 2.47 (s, 3H); 3.75 (s, 3H); 5.20 (s, 2H); 7.15 (d, 1H, J=5.37 Hz); 7.46 (d, 1H, J=5.37 Hz).
I.R. νKBr (cm-1): 3110, 2920, 1750, 1550, 1420, 1220, 1100.
Mass: m/z 270 [M+ ]
Starting Material: N-(2-phenylthio-3-thenoyl)glycine methyl ester
N.M.R. (CDCl3) δppm: 3.73 (s, 3H); 5.10 (s, 2H); 7.21˜7.27 (M, 6H); 7.55 (d, 1H, J=5.37 Hz).
I.R. νNaCl (cm-1): 3100, 2950, 1750, 1570, 1480, 1440, 1360, 1220, 1000.
Mass: m/z 332 [M+ ]
Starting Material: N-(5-phenylthio-2-thenoyl)glycine methyl ester
M.P.: 102-103° C.
N.M.R. (CDCl3) δppm: 3.82 (s, 3H); 5.30 (s, 2H); 7.26˜7.37 (m, 6H); 7.49 (d, 1H, J=3.91 Hz).
I.R. νKBr (cm-1): 2900, 1750, 1570, 1480, 1430, 1410, 1360, 1220, 1100, 800.
Mass: m/z 332 [M+ ]
Starting Material: N-[5-(N',N'-diethylaminosulfonyl)-2-thenoyl)-glycine methyl ester
N.M.R. (CDCl3) δppm: 1.08 (t, 6H; J=7.20 Hz); 3.07 (g, 4H, J=7.20 Hz); 3.72 (s, 3H); 5.23 (s, 2H); 7.22 (d, 1H, J=5.12 Hz); 7.67 (d, 1H, J=5.12 Hz).
I.R. νNaCl (cm-1): 3100, 2950, 1750, 1610, 1440, 1350, 1220, 1150, 940, 700.
Mass: m/z 347 [M+ ]
Starting Material: N- [5-(N',N'-dibutylaminosulfonyl)-2-thenoyl)-glycine methyl ester
N.M.R. (CDCl3) δppm: 0.86 (t, 6H, J=7.32 Hz); 1.33˜1.37 (m, 4H); 1.40˜1.48 (m, 4H); 2.04 (t, 4H, J=7.32 Hz); 3.71 (s, 3H); 5.23 (s, 2H); 7.22 (d, 1H, J=5.25 Hz); 7.67 (d, 1H, J=5.25 Hz).
I.R. νNaCl (cm-1): 2950, 1760, 1360, 1220, 1150.
Mass: m/z 415 [M+ ]
Starting Material: N-(5-piperidinosulfonyl-2-thenoyl)glycine methyl ester
M.P.: 133-135° C.
N.M.R. (CDCl3) δppm: 1.04˜1.53 (m, 2H); 1.59˜1.68 (m, 4H); 2.92 (t, 4H, J=5.25 Hz); 3.71 (s, 3H); 5.23 (s, 2H); 7.26 (d, 1H, J=5.13 Hz); 7.72 (d, 1H, J=5.13 Hz).
I.R. νKBr (cm-1): 3100, 2950, 1760, 1340, 1220, 1150, 940, 710, 590.
Mass m/z 371 [M+ ](3-17) methyl [5- [2-(N,N-diethylaminosulfonyl)-5-trimethylsilyl-3-thienyl] tetrazol-1-yl] acetate; (yield=75.4%)
Starting Material: N- [2-(N',N'-diethylaminosulfonyl)-5-trimethylsilyl-3-thenoyl] glycine methyl ester
N.M.R. (CDCl3) δppm: 0.37 (s, 9H); 1.08 (t, 6H, J=7.20 Hz); 3.06 (g, 4H, J=7.08 Hz); 3.71 (s, 3H); 5.21 (s, 2H); 7.24 (s, 1H).
I.R. νNaCl (cm-): 2950, 1760, 1440, 1350, 1250, 1220, 1140, 1000, 840, 700.
Mass m/z 431 [M+ ]
Starting Material: N-(3-hydroxy-2 thenoyl)glycine methyl ester
M.P.=141-142° C.
N.M.R. (CDCl3) δppm: 3.84 (s, 3H); 5.38 (s, 2H); 6.95 (d, 1H, J=5.37 Hz); 7.46 (d, 1H, J=5.37 Hz); 10.12 (bs, 1H).
I.R. νKBr (cm-1): 3100, 1760, 1740, 1530, 1220, 1000.
Mass: m/z 240 [M+ ]
The compounds prepared in the foregoing Examples are listed in the following Table I.
TABLE I
______________________________________
Ex.
No. R.sub.1 R.sub.2 X
______________________________________
1-1 --CH.sub.3
H S (2)*.sup.2
1-2 --CH.sub.3
--CH.sub.3 (3)*.sup.1 S (2)
1-3 --CH.sub.3
--CH.sub.3 (4) S (2)
1-4 --CH.sub.3
--CH.sub.3 (5) S (2)
1-5 --CH.sub.3
H S (3)
1-6 --CH.sub.3
H O (2)
1-7 --CH.sub.3
H O (3)
1-8 --CH.sub.3
--CH.sub.2 CH.sub.3 (5) S (2)
1-9 --CH.sub.3
--CH.sub.2 -on (5) S (2)
1-10 --CH.sub.3
--SCH.sub.3 5) S (2)
1-11 --CH.sub.3
--Br (5) S (2)
1-12 --CH.sub.3
--CH.sub.3 (2) S (2)
1-13 --CH.sub.3
--CH.sub.2 Br (5) S (2)
1-14 --CH.sub.3
on (5)
S (2)
1-15 --CH.sub.3
--NHCOCH.sub.3 (3) S (2)
1-16 --CH.sub.3
--NHCOCH.sub.2 CH.sub.2 CH.sub.3 (3)
S (2)
1-17 --CH.sub.3
--NHCOCH.sub.2 CH.sub.2 -on (3)
S (2)
1-18 --CH.sub.3
--CH.sub.3 (5) O (2)
1-19 --CH.sub.3
--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (5)
O (2)
1-20 --CH.sub.3
--Br (5) O (2)
1-21 --CH.sub.3
--SCH.sub.3 (5) O (2)
1-22 --CH.sub.3
--Br (2) O (3)
1-23 --CH.sub.3
--CH(n-C.sub.3 H.sub.7)--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
(2) O (3)
1-24 --CH.sub.3
--SCH.sub.3 (2) O (3)
1-25 --CH.sub.3
--NHSO.sub.2 CH.sub.3 (3)
S (2)
1-26 --CH.sub.3
--NHSO.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
S (2)
1-27 --CH.sub.3
--NHSO.sub.2 on (3) S (2)
1-28 --CH.sub.3
--CH.sub.3 (2) O (3)
1-29 --CH.sub.3
--SO.sub.2 N(CH.sub.3)--CH.sub.2 CH.sub.2 OCH.sub.2 OCH.sub.3
(5) S (2)
2-1 --H H S (2)
2-2 --H --CH.sub.3 (3) S (2)
2-3 --H --CH.sub.3 (4) S (2)
2-4 --H --CH.sub.3 (5) S (2)
2-5 --H H S (3)
2-6 --H H O (2)
2-7 --H H O (3)
2-8 --H --C.sub.2 H.sub.5 (5) S (2)
2-9 --H --CH.sub.2 -on (5) S (2)
2-10 --H --SCH.sub.3 (5) S (2)
2-11 --H --Br (5) S (2)
2-12 --H --CH.sub.3 (2) S (3)
2-13 --H --CH.sub.2 Br (5) S (2)
2-14 --H
on (5)
S (2)
2-15 --H --OCH.sub.3 (3) S (2)
2-16 --H --OCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (3)
S (2)
2-17 --H --NHCOCH.sub.3 (3) S (2)
2-18 --H --NHCOCH.sub.2 CH.sub.2 CH.sub.3 (3)
S (2)
2-19 --H --NHCOCH.sub.2 CH.sub.3 -on (3)
S (2)
2-20 --H --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (5)
S (2)
2-21 --H --CH.sub.2 CH.sub.2 CH.sub.3 -on (5)
S (2)
2-22 --H --CH.sub.2 OCH.sub.3 (5)
S (2)
2-23 --H --CH.sub.2 OCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
S (2)
2-24 --H --Br (2) S (3)
2-25 --H --CH(n-C.sub.3 H.sub.7)--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2
(2) S (3)
2-26 --H --SCH.sub.3 (2) S (3)
2-27 --H --CH.sub.3 (5) O (2)
2-28 --H --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (5)
O (2)
2-29 --H --Br (5) O (2)
2-30 --H --SCH.sub.3 (5) O (2)
2-31 --H --Br (2) O (3)
2-32 --H --SCH.sub.3 (2) O (3)
2-33 --H --S-on (2) S (3)
2-34 --H --S-on (5) S (2)
2-35 --H --SO.sub.2 --N(C.sub.2 N.sub.5).sub.2 (5)
S (2)
2-36 --H --SO.sub.2 --NCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3).sub.2
S (2)
2-37 --H --SO.sub.2 -on (5) S (2)
2-38 --H --SO.sub.2 --N(C.sub.2 H.sub.5).sub.2 (2)
S (3)
2-39 --H --NHSO.sub.2 CH.sub.3 (3)
S (2)
2-40 --H --NHSO.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
S (2)
2-41 --H --NHSO.sub.3 -on (3) S (2)
2-42 --H --ON (3) S (2)
2-43 --H --SOCH.sub.3 (2) S (3)
2-44 --H --SO.sub.2 CH.sub.3 (2) S (3)
2-45 --H --NH.sub.2 HCl (3) S (2)
2-46 --H --SO.sub.2 --N(CH.sub.3)--CH.sub.2 CH.sub.2 OH
S (2)
3-1 --CH.sub.3
H S (2)
3-2 --C.sub.2 H.sub.5
H S (3)
3-3 --CH.sub.3
--OCH.sub.3 (3) S (2)
3-4 --CH.sub.3
--OCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (3)
S (2)
3-5 --CH.sub.3
--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 (5)
S (2)
3-6 --CH.sub.3
--CH.sub.2 CH.sub.2 CH.sub.2 -on (5)
S (2)
3-7 --CH.sub.3
--CH.sub.2 OCH.sub.3 (5)
S (2)
3-8 --CH.sub.3
--CH.sub.2 OCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
S (2)
3-9 --CH.sub.3
--Br (2) S (3)
3-10 --CH.sub.3
--CH(n-C.sub.3 H.sub.7)CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3
(2) S (3)
3-11 --CH.sub.3
--SCH.sub.3 (2) S (3)
3-12 --CH.sub.3
--S-on (2) S (3)
3-13 --CH.sub.3
--S-on (5) S (2)
3-14 --CH.sub.3
--SO.sub.2 --N(C.sub.3 H.sub.5).sub.2 (5)
S (2)
3-15 --CH.sub.3
--SO.sub.2 --N(n-C.sub.3 H.sub.5).sub.2 (5)
S (2)
3-16 --CH.sub.3
--SO.sub.2 -on (5) S (2)
3-17 --CH.sub.3
--SO.sub.2 --N(C.sub.2 H.sub.5).sub.2 (2)
S (3)
--Si(CH.sub.3).sub.3 (%)
3-18 H --OH (3) S (2)
______________________________________
In Table I on" and pip" means a phenyl and piperidine groups respectively
*.sup.1 Each numeral given in parentheses means the position on the
thiophene or furan ring at which each substituent is bonded.
*.sup.2 Each numeral given in parentheses means the position on the
thiophene or furan ring at which the tetrazolyl group is bonded at its
5position.
.[.thiophene or furan ring at which the tetrazolyl group is bonded at its 5-position..].
As has been explained above in detail, the aldose reductast inhibitor of the present invention shows excellent aldose reductase inhibitory effect and has low toxicity. Therefore, it can be used as a medicine for preventing and/or treating mammalian inclusive of man suffering from diabetic complications such as neural disorders, nephrosis, cataract and retinopathy with safety.
The effects and toxicity of the aldose reductase inhibitor according to the present invention will be detailed below with reference to the following Test Examples.
Six-weeks-old male SD rates were anesthetized with ether and killed. Then their crystalline lenses were immediately removed and stored at -80° C. The lenses were homogenized in 3 volume of 135 mM sodium potassium phosphate buffer (pH 7.0) and centrifuged at 30,000 rpm for 30 minutes. the resulting supernatant was dialyzed overnight against 0.05 M sodium chloride solution to obtain an aldose reductase solution. All operations were conducted at 4° C. and the enzyme solution was stored at -80° C.
The activity of aldose reductase was determined according to a partially modified method of J.H. Kinoshita et al (J. Bio. Chem., 1965, 240, p. 877). More specifically, 0.1 ml of DL glyceraldehyde (final concentration: 10 mM) was added to 0.9 ml of 100 mM sodium potassium phosphate buffer (pH 6.2) which contained lithium sulfate (final concentration: 400 mM), reduced nicotinamide adenine dinucleotide phosphate (final concentration: 0.15 mM), the enzyme solution, and the compound to be evaluated (final concentration: 10-6 M, 10-7 M or 1031 8 M), and then the reaction was conducted at 30° C. for 5 minutes. During the reaction, the change in the absorbance at 340 nm with time was monitored. The maximum reducing rate of the absorbance (U) during the reaction was determined. By subtracting, from this value, the maximum reducing rate (Uo) at 340 nm of the reaction solution before the addition of the substrate (DL-glyceraldehyde), the reaction rate (V=U-Uo) was calculated as a true reaction rate in the presence of the compound to be tested.
The same procedure was repeated except for the absence of the compound to be tested. A true reaction rate (Vo) in case the enzyme was not inhibited was calculated (Vo =U'-Uo '). The aldose reductase inhibitory activity of the test compounds was determined according to the following formula:
Rate of Inhibition (%)=(V.sub.o -V)/V.sub.o ×100
For comparison, the same tests were conducted using a known aldose reductase inhibitor: ONO-2235 [(E)-3-carboxymethyl-5- [(2E)-methyl-3-phenylpropenylidene] rhodan].
The results thus obtained are summarized in the following Table II. As seen from Table II, the compounds of the present invention tested show aldose reductase inhibitory effect identical to or superior to those attained by the known inhibitor ONO-2235.
TABLE II ______________________________________ Compound Tested IC.sub.50 (Ex. No.) (10.sup.-4) M ______________________________________ 1-5 96 1-7 74 1-27 23 2-1 1.6 2-2 1.8 2-3 2.4 2-4 2.3 2-5 2.1 2-6 6.0 2-7 3.0 2-8 2.1 2-9 2.0 2-10 2.0 2-11 1.9 2-12 1.0 2-13 2.5 2-14 2.1 2-15 2.9 2-16 3.1 2-17 2.8 2-18 2.0 2-19 2.4 2-20 2.3 2-21 2.8 2-22 3.1 2-23 2.5 2-24 3.8 2-26 3.1 2-27 15 2-28 13 2-29 16 2-30 11 2-31 8.5 2-32 3.5 2-33 2.4 2-34 2.6 2-35 39 2-36 8.5 2-37 23 2-38 46 2-39 2.8 2-40 1.6 2-41 2.3 2-42 2.0 2-43 30 2-44 52 3-2 58 3-5 18 3-11 38 ONO-2235 2.2 ______________________________________
Groups of 6 to 8-weeks-old Sprague-Dawley male rats (4 aminals per group) were fasted for 18 hours and streptozotocin was injected through the tail vein in a dose of 60 mg/kg to thus obtain diabetic rats. Immediately after the administration of the streptozotocin, each compound to be tested was orally administered to these rats in the form of a suspension at a dose of 10 mg/kg, 30 mg/kg and 50 mg/kg (each was suspended in a 0.5% sodium carboxymethyl cellulose solution) twice a day (9 o'clock in the morning and 5 o'clock in the afternoon) for 5 days. During the test, the rats took diet and drank water freely. 4 Hours after the final administration of the drug in the 5th day's morning (9 o'clock in the morning), the rats were sacrificed and then the sciatic nerve thereof was removed to determine the amount of sorbitol accumulated therein.
The results are expressed in the percentage obtained while the value obtained on the control to which any drug was not administered is defined to be 100.
The results of the test are listed in the following Table III. These results indicate that the compounds of the present invention shown high inhibitory effect as compared with those for the known aldose reductase inhibitor ONO-2235.
TABLE III
______________________________________
Rate of Inhibition of
Compound Tested Sorbitol Accumulation (%)
(Ex. No.) 10 mg/kg 30 mg/kg 50 mg/kg
______________________________________
2-1 68 89 --
2-2 62 93 --
2-5 73 90 --
2-7 46 77 --
ONO-2235 0 0 40
______________________________________
Each compound to be tested was suspended to 0.5% sodium carboxymethyl cellulose solution and the resulting suspension was orally administered to 6-weeks-old male MCH mice (5 animals per test group). The 50% lethal dose (LD50 ; mg/kg) was evaluated from the mortality rate (%) observed 14 days after the administration of the compound. The mice took diet and drank water freely during the test.
The results obtaind are summarized in the following Table IV. As seen from Table IV, the compounds of the present invention which were subjected to the foregoing test show LD50 of not less than 3,000 mg/kg.
TABLE IV
______________________________________
Compound Tested (Ex. No.)
LD.sub.50 (mg/kg)
______________________________________
2-1 >3.000
2-2 >3.000
2-3 >3.000
______________________________________
Claims (20)
1. A tetrazoleacetic acid derivative represented by the following general formula (I): ##STR8## .[.[Formula (I).]. .Iadd.wherein.Iaddend., R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an alkoxyalkyl group, an amino group, .[.an aryl group,.]. an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--.[.].]. except for .[.[.]..Iadd.(.Iaddend.5-(2-(thienyl)tetrazol-1-yl).[.].]. acetic acid, .[.[.]..Iadd.(.Iaddend.5-(2-(furyl)tetrazol-1-yl).[.].]. acetic acid.Iadd., (5-(5-bromo-2-furyl)tetrazol-1-acetic acid, (5-(5-phenylthio-2-furyl)tetrazol-1-yl)acetic acid, (5-(5-phenylsulfonyl-2-furyl)tetrazol-1-yl)acetic acid .Iaddend.and ethyl esters thereof, or a .Iadd.pharmaceutically acceptable .Iaddend.salt thereof.
2. The tetrazoleacetic acid derivative of claim 1 wherein, in the general formula (I), the alkyl group represented by R1 or R2 is selected from the gorup consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl groups.[.,.]. .Iadd.; .Iaddend.the aralkyl group is a benzyl or phenylpropyl group; the alkoxy group is a member selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and t-butoxy groups.[.,.]. .Iadd.; .Iaddend.the alkoxyalkyl group is a methoxymethyl or butoxymethyl group; the haloalkyl group is a mono-, di or tri-haloalkyl group; the alkyl or aryl thio group is a member selected from the group consisting of methylthio, ethylthio, butylthio and phenylthio groups; the alkylaminosulfonyl group is a mono- or di-alkylaminosulfonyl group; the alkyl or aryl sulfonylamino group is a member selected from the group consisting of methylsulfonylamino, ethylsulfonylamino, butylsulfonylamino and phenylsulfonylamino groups; the alkyl or aryl carbonylamino group is a member selected from the group consisting of methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino and phenethylcarbonylamino groups; the alkyl or aryl sulfonyl group is a member selected from the group consisting of methylsulfonyl, ethylsulfonyl, butylsulfonyl and piperidinosulfonyl groups; and the alkylsulfinyl group is a member selected from the group consisting of methylsulfinyl, ethylsulfinyl and butylsulfinyl groups.
3. The tetrazoleacetic acid derivative of claim 2 wherein the haloalkyl group is a member selected from the group consisting of chloromethyl, bromomethyl, fluoromethyl and chlorobutyl groups; and the alkylaminosulfonyl group is a member selected from the group consisting of methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl and butylaminosulfonyl groups.
4. The tetrazoleactic acid derivative of claim 1 wherein the salt of the compound represented by Formula (I) wherein R1 is a hydrogen atom is a member selected from the group consisting of alkali metal salts, alkaline earth metal salts, ammomium salts, organic amine salts and salts with basic amino acids.
5. The tetrazoleacetic acid derivative of claim 4 wherein the alkali metal salt is a sodium salt or a potassium salt; the alkaline earth metal salt is a calcium salt or a magnesium salt; the organic amine salt is a triethylamine salt, a pyridine salt or an ethanolamine salt; and the basic amino acid salt is an arginine salt.
6. The tetrazoleacetic acid derivative of claim 1 wherein, in the foregoing Formula (I), R1 is a hydrogen atom and X is an oxygen or sulfur atom.
7. An aldose reductase inhibitor comprising a tetrazoleacetic acid derivative represented by the following general formula (II): ##STR9## .[.[Formula (II).]. .Iadd.wherein.Iaddend., R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, and alkoxy group, an alkoxyalkyl group, an amino group, .[.an aryl group,.]. an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl gorup or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--.[.].]. or a .Iadd.pharmaceutically acceptable .Iaddend.salt thereof and a pharmaceutically acceptable carrier.
8. The aldose reductase inhibitor of claim 7 wherein, in the general formula (II), the lower alkyl group represented by R1 or R2 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl groups; the aralkyl group is a benzyl or phenylpropyl group; the alkoxy group is a member selected from the group consiting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and t-butoxy groups; the alkoxyalkyl group is a methoxymethyl or butoxymethyl group; the haloalkyl gorup is a mono-, di or tri-haloalkyl group; the alkyl or aryl thio group is a member selected from the group consisting of methylthio, ethylthio, butylthio and phenylthio groups; the alkylaminosulfonyl group is a mono- or di-alkylaminosulfonyl group; the alkyl or aryl sulfonylamino group is a member selected from the group consisting of methylsulfonylamino, ethylsulfonylamino, butylsulfonylamino and phenylsulfonylamino groups; the alkyl or aryl carbonylamino group is a member selected from the group consisting of methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino and phenethylcarbonylamino groups; the alkyl or aryl sulfonyl group is a member selected from the group consisting of methylsulfonyl, ethylsulfonyl, butylsulfonyl and piperidinosulfonyl groups; and the alkylsulfinyl group is a member selected from the group consisting of methylsulfinyl, ethylsulfinyl and butylsulfinyl groups.
9. The aldose reductase inhibitor of claim 8 wherein the haloalkyl group is a member selected from the group consisting of chloromethyl, bromomethyl, fluoromethyl and chlorobutyl groups; and the alkylaminosulfonyl group is a member selected from the group consisting of methylaminosulfonyl, ethylaminosulfonyl, propylsaminosulfonyl and butylaminosulfonyl groups.
10. The aldose reductase inhibitor of claim 7 wherein the salt of the compound represented by Formula (II) wherein R1 is a hydrogen atom is a member selected form the group consisting of alkali metal salts, alkaline earth metal salts, ammonium salts, organic amine salts and salts with basic amino acids.
11. The aldose reductase inhibitor of claim 10 wherein the alkali metal salt is a sodium salt or a potassium salt; the alkaline earth metal salt is a calcium salt or a magnesium salt; the organic amino salt is a triethylamine salt, a pyridine salt or an ethanolamine salt; and the basic amino acid salt is an arginine salt.
12. The aldose reductase inhibitor of claim 7 wherein, in Formula (II), R1 is a hydrogen atom and X is an oxygen or sulfur atom.
13. A method for alleviating or reducing diabetic complications wherein .Iadd.an effective amount of .Iaddend.a tetrazoleacetic acid derivative represented by the following general formula (II): ##STR10## .[.[in Formula (II).]. .Iadd.wherein.Iaddend., R1 represents a hydrogen atom or an alkyl group; R2 represents a hydrogen atom, an alkyl group, an aralkyl group, a halogen atom, a haloalkyl group, a hydroxyl group, an alkoxy group, an an alkoxyalkyl group, an amino group, .[.an aryl group,.]. an alkyl or aryl thio group, an alkyl or aryl carbonylamino group, an alkyl or aryl sulfonylamino group, an alkyl or aryl aminosulfonyl group, an alkyl or aryl sulfonyl group or an alkyl or aryl sulfinyl group; and X represents --O-- or --S--.[.].]. or a .Iadd.pharmaceutically acceptable .Iaddend.salt thereof is .[.used.]. .Iadd.administered.Iaddend..
14. The method of claim 13 wherein, in the general formula (II), the alkyl group represented by R1 and R2 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl groups; the aralkyl group is a benzyl or phenylpropyl group; the alkoxy group is a member selected from the group consisting of methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and t-butoxy groups; the alkoxyalkyl group is a methoxymethyl or butoxymethyl group; the haloalkyl group is a mono-, di or tri-haloalkyl group; the alkyl or aryl thio group is a member selected from the group consisting of methylthio, ethylthio, butylithio and phenylthio groups; the alkylaminosulfonyl group is a mono- or di-alkylaminosulfonyl group; the alkyl or aryl sulfonylamino group is a member selected from the group consisting of methylsulfonylamino, ethylsulfonylamino, butysulfonylamino and phenylsulfonylamino groups; the alkyl or aryl carbonylamino group is a member selected from the group consisting of methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino and phenethylcarbonylamino groups; the alkyl or aryl sulfonyl group is a member selected from the group consisting of methylsulfonyl, ethylsulfonyl, butylsulfonyl and piperidinosulfonyl groups; and the alkylsulfinyl group is a member selected from the group consisting of methylsulfinyl, ethylsulfinyl and butylsulfinyl groups.
15. The method of claim 14 wherein the haloalkyl group is a member selected form the group consisting of chloromethyl, bromomethyl, fluoromethyl and chlorobutyl groups; and the alkylaminosulfonyl group is a member selected from the group consisting of methylaminosulfonyl, ethylaminoslfonyl, propylaminosulfonyl and butylaminosulfonyl groups.
16. The method of claim 13 wherein the salt of the compound represented by Formula (II) wherein R1 is a hydrogen atom is a member selected from the group consisting of alkali metal salts, alkaline earth metal salts, ammonium salts, organic amine salts and salts with basic amino acids.
17. The method of claim 16 wherein the alkali metal salt is a sodium salt or a potassium salt; the alkaline earth metal salt is a calcium salt or a magnesium salt; the organic amine salt is a triethylamine salt, a pyridine salt or an ethanolamine salt; and the basic amino acid salt is an arginine salt.
18. The method of claim 13 wherein, in Formula (II), R1 is a hydrogen atom and X is an oxygen or sulfur atom.
19. The method of claim 13 wherein the compound is administered, at one time or over several times, in an amount ranging from 1 to 1,000 mg per day for adult, orally, subcutaneously, intravenously or locally.
20. The method of calim 13 wherein the compound is administered in the form of tablets, powder, fine particles, granules, capsules, pills, liquid preparations, solutions or suspensions for injection or eye drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/951,720 USRE35321E (en) | 1989-10-03 | 1992-09-25 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25708689 | 1989-10-03 | ||
| JP1-257086 | 1989-10-03 | ||
| US07/588,057 US5068239A (en) | 1989-10-03 | 1990-09-24 | Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory activity |
| US07/951,720 USRE35321E (en) | 1989-10-03 | 1992-09-25 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/588,057 Reissue US5068239A (en) | 1989-10-03 | 1990-09-24 | Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE35321E true USRE35321E (en) | 1996-08-27 |
Family
ID=17301550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/588,057 Ceased US5068239A (en) | 1989-10-03 | 1990-09-24 | Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory activity |
| US07/951,720 Expired - Lifetime USRE35321E (en) | 1989-10-03 | 1992-09-25 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/588,057 Ceased US5068239A (en) | 1989-10-03 | 1990-09-24 | Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory activity |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5068239A (en) |
| EP (1) | EP0421365B1 (en) |
| JP (1) | JPH03204875A (en) |
| DE (1) | DE69030044T2 (en) |
| HU (2) | HU215432B (en) |
| RU (2) | RU2052458C1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605795A (en) * | 1986-07-24 | 1997-02-25 | Tropix, Inc. | Assays using chemiluminescent, enzymatically cleavable substituted 1,2-dioxetanes and kits therefor |
| JPH04297474A (en) * | 1991-03-26 | 1992-10-21 | Wakamoto Pharmaceut Co Ltd | Tetrazoleacetic acid derivative |
| GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| US5262433A (en) * | 1991-08-06 | 1993-11-16 | Wakamoto Pharmaceutical Co., Ltd. | Tetrazoleacetic acid derivatives and method of aldose reductase inhibition therewith |
| AU2002213048A1 (en) * | 2000-10-05 | 2002-04-15 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
| AU2015215863C1 (en) * | 2009-02-06 | 2016-10-20 | Imago Pharmaceuticals, Inc. | Inhibitors of jun n-terminal kinase |
| WO2010091310A1 (en) | 2009-02-06 | 2010-08-12 | Elan Pharmaceuticals, Inc. | Inhibitors of jun n-terminal kinase |
| JPWO2019194220A1 (en) * | 2018-04-06 | 2021-05-13 | 日本曹達株式会社 | (Hetero) aryl sulfonamide compounds and pest control agents |
| AU2019297402B2 (en) * | 2018-07-05 | 2024-05-02 | Bayer Aktiengesellschaft | Substituted thiophenecarboxamides and analogues as antibacterials agents |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4886885A (en) * | 1987-10-28 | 1989-12-12 | Lilly Industries Limited | Compound containing tetrazolyl groups and their use for treating allergies and cardiovascular disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
-
1990
- 1990-09-05 JP JP2233220A patent/JPH03204875A/en active Granted
- 1990-09-24 US US07/588,057 patent/US5068239A/en not_active Ceased
- 1990-10-02 HU HU6305/90A patent/HU215432B/en not_active IP Right Cessation
- 1990-10-02 RU SU904831469A patent/RU2052458C1/en active
- 1990-10-03 DE DE69030044T patent/DE69030044T2/en not_active Expired - Fee Related
- 1990-10-03 EP EP90118900A patent/EP0421365B1/en not_active Expired - Lifetime
-
1992
- 1992-09-25 US US07/951,720 patent/USRE35321E/en not_active Expired - Lifetime
-
1994
- 1994-08-24 RU RU94031212/04A patent/RU94031212A/en unknown
-
1995
- 1995-06-06 HU HU95P/P00166P patent/HU211166A9/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4886885A (en) * | 1987-10-28 | 1989-12-12 | Lilly Industries Limited | Compound containing tetrazolyl groups and their use for treating allergies and cardiovascular disease |
Non-Patent Citations (29)
| Title |
|---|
| A. K. Sorensen et al., Syntheses of Some New Tetrazolylacetic Acids and the Corresponding 3 Substituted Propionic Acids, Acta Chem. Scand. 26:541 548 (1972). * |
| A. K. Sorensen et al., Syntheses of Some New Tetrazolylacetic Acids and the Corresponding 3-Substituted Propionic Acids, Acta Chem. Scand.26:541-548 (1972). |
| C. R. Jacobson and E. D. Amstutz, Studies in Tetrazole Chemistry, IV. Tetrazolylacenic Acids and Esters. J. Org. Chem. 21:311 315. 1955. * |
| C. R. Jacobson and E. D. Amstutz, Studies in Tetrazole Chemistry, IV. Tetrazolylacenic Acids and Esters. J. Org. Chem. 21:311-315. 1955. |
| Chem. Abstract 106:33069q, 1987. * |
| Chem. Abstract 106:84617z, 1987. * |
| Chem. Abstract 109:37780z, 1988. * |
| Chem. Abstract 111:57646e, 1989. * |
| Chem. Abstract 111:77925y, 1989. * |
| Fred Einberg, Alkylation of 5 Substituted Tetrazoles with a Chlorocarbonyl Compounds, J. Org. Chem. 35:3978 3980. 1970. * |
| Fred Einberg, Alkylation of 5-Substituted Tetrazoles with a --Chlorocarbonyl Compounds, J. Org. Chem. 35:3978-3980. 1970. |
| G. Szeimies et al., Synthese und Thermeisches Verhalten Ciniger 3 Aryl 3 Axido Aziridin 2 Carbonsaure Ethylester, Chem. Ber. 110:2922 2938. 1977. * |
| G. Szeimies et al., Synthese und Thermeisches Verhalten Ciniger 3-Aryl-3-Axido-Aziridin-2-Carbonsaure-Ethylester, Chem. Ber. 110:2922-2938. 1977. |
| G. Szeimies et al., Synthese und Thermisches Verhalten Ciniger 3 Aryl 3 Azido Aziridin 2 Carbonsaure Ethylester, Chem. Ber. 110:2922 2938 (1977). * |
| G. Szeimies et al., Synthese und Thermisches Verhalten Ciniger 3-Aryl-3-Azido-Aziridin-2-Carbonsaure--Ethylester, Chem. Ber. 110:2922-2938 (1977). |
| L ubomir Janda et al, Semisynthetic Cephalosporines, Synthesis of Some Substituted Tetrazolyl Acetic and Propionic Acids. Coll. Czech. Chem. Commun. 49:1699 1713. 1984. * |
| L ubomir Janda et al., Semisynthetic Cephalosporines, the Synthesis of Some Substituted Tetrazolylacetic Acids, Cll Czech Chem Commun 49:1505 1514. 1984. * |
| L. Janda and Z. Voticky, Synthesis of Some Substituted Tetrazolylacetic Acids and the Corresponding 3 substituted Propionic Acids. Acta. Chem. Scand. 26:541 548. 1972. * |
| L. Janda and Z. Voticky, Synthesis of Some Substituted Tetrazolylacetic Acids and the Corresponding 3-substituted Propionic Acids. Acta. Chem. Scand. 26:541-548. 1972. |
| L'ubomir Janda et al, Semisynthetic Cephalosporines, Synthesis of Some Substituted Tetrazolyl Acetic and Propionic Acids. Coll. Czech. Chem. Commun. 49:1699-1713. 1984. |
| L'ubomir Janda et al., Semisynthetic Cephalosporines, the Synthesis of Some Substituted Tetrazolylacetic Acids, Cll Czech Chem Commun 49:1505-1514. 1984. |
| R. Rapp and J. Howard, Tetrazolylacetic acids, Can. J. Chem. 47:813 819. 1969. * |
| R. Rapp and J. Howard, Tetrazolylacetic acids, Can. J. Chem. 47:813-819. 1969. |
| Robert T. Buckler et al, Synthesis and Antiinflammatory Activity of some Aryltetrazolyalkanoic Acids. J. Med. Chem. 13:725 729. 1970. * |
| Robert T. Buckler et al, Synthesis and Antiinflammatory Activity of some Aryltetrazolyalkanoic Acids. J. Med. Chem. 13:725-729. 1970. |
| V. S. Poplavskii et al., Tetrazoles Zhumai organicheskoi khimii. 1982. XVIII. No. 9. 1977. 1981 85. * |
| V. S. Poplavskii et al., Tetrazoles Zhumai organicheskoi khimii. 1982. XVIII. No. 9. 1977. 1981-85. |
| V. S. Poplavskii et al., Tetrazoles Zhurnal organicheskoi khimii, 1982, XVIII, No. 9, 1981 1985. * |
| V. S. Poplavskii et al., Tetrazoles Zhurnal organicheskoi khimii, 1982, XVIII, No. 9, 1981-1985. |
Also Published As
| Publication number | Publication date |
|---|---|
| HUT59132A (en) | 1992-04-28 |
| EP0421365A2 (en) | 1991-04-10 |
| JPH0583551B2 (en) | 1993-11-26 |
| EP0421365A3 (en) | 1992-01-02 |
| HU215432B (en) | 1999-04-28 |
| US5068239A (en) | 1991-11-26 |
| DE69030044D1 (en) | 1997-04-10 |
| HU211166A9 (en) | 1995-11-28 |
| DE69030044T2 (en) | 1997-10-09 |
| RU94031212A (en) | 1996-08-10 |
| JPH03204875A (en) | 1991-09-06 |
| RU2052458C1 (en) | 1996-01-20 |
| EP0421365B1 (en) | 1997-03-05 |
| HU906305D0 (en) | 1991-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06500557A (en) | Indole derivatives that inhibit leukotriene biosynthesis | |
| US6727239B1 (en) | Derivatives of 2-aminopyridines, their use as medicaments and pharmaceutical compositions containing them | |
| JP3067809B2 (en) | Novel substituted 2,4-thiazolidinedione derivative, method for producing the same, and pharmaceutical composition containing the same | |
| AU661609B2 (en) | New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them | |
| USRE35321E (en) | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | |
| EP0589037B1 (en) | Indian derivative and thromboxane antagonist containing the same | |
| JP3226920B2 (en) | Therapeutic compositions based on 1,2-dithiol-3-thione derivatives | |
| CA2263348C (en) | Pharmaceutical composition containing 4-oxo-butynic acids | |
| JP2005527518A (en) | Novel chalcone derivatives and their use | |
| US5102905A (en) | Thienyl benzothienyl and dibenzothienyl compounds as inhibitors of aldose reductase | |
| JPS60184074A (en) | 2-sulfamoylbenz(b)furan derivative for treating high intraocular pressure | |
| US5750524A (en) | Remedy for hyperlipidemia | |
| US20110171300A1 (en) | Delta 9 tetrahydrocannabinol derivatives | |
| CN100430392C (en) | Carbamoyl-type benzofuran derivatives | |
| US20050014817A1 (en) | Fluorothiophene derivatives, process for preparing them and pharmaceutical compositions containing them | |
| US4968680A (en) | 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives, process for producing them and use thereof | |
| US5262433A (en) | Tetrazoleacetic acid derivatives and method of aldose reductase inhibition therewith | |
| DE2653621A1 (en) | CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| DD234008A5 (en) | FLAVENE AND THIOFLAVENE DERIVATES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL PREPARATION STATE CONTAIN SEARCH COMPOUNDS, AND THE USE OF THE LATTER | |
| JPS6212795B2 (en) | ||
| DD222311A5 (en) | PROCESS FOR PRODUCING NEW FLAVANONE AND THIOFLAVANONE | |
| JP2001506645A (en) | Novel 4- (1-piperazinyl) benzoic acid derivatives, their preparation methods and their therapeutic use | |
| US5252592A (en) | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | |
| US4192884A (en) | Substituted 4-(((thienyl)methyl)-amino)benzoic acids and a method for treating hypolipidemia | |
| KR840002307B1 (en) | Process for preparing 5-substituted pyranone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |